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DEDICATION 
 
This thesis is especially dedicated to children suffering with epilepsy. 
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ABSTRACT 
 
Convulsive status epilepticus (CSE) is an emergency condition associated with 
mortality and morbidity. It is commonly treated with antiepileptic drugs (AEDs), but 
these may cause serious adverse events and even death in children. Research on their 
effectiveness for CSE, and related adverse events in children remains limited. The 
primary aim of this research was thus to evaluate the effectiveness and safety of AEDs 
in treating acute tonic-clonic seizure including convulsive status epilepticus (CSE). Two 
systematic reviews and meta-analyses were conducted to address these aims. The first 
evaluated the effectiveness of AEDs in children with acute tonic-clonic seizures 
including (CSE). The second evaluated the safety of AEDs in this population. 
The systematic review of AED effectiveness identified 20 studies published between 
1946 and April 2015. It showed that buccal midazolam was more effective than rectal 
diazepam for treating acute tonic-clonic seizures including CSE in children, and was 
associated with a lower recurrence rate. Lorazepam and diazepam were equally 
effective in terminating seizures, but for lorazepam, intravenous administration was 
more effective than the buccal, sublingual or intranasal routes. Intravenous valproate 
appeared to be more effective than intravenous phenytoin and phenobarbital; however, 
the difference was not significant. 
The systematic review of AED safety for children with acute tonic-clonic seizures 
identified 25 studies, published between 1946 and April 2015. These studies were 
predominantly randomised controlled trials and of these 19 studies reported more than 
one adverse event, while 6 reported none. A total of 203 adverse events were 
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documented, most commonly respiratory depression (101 children), mainly after 
treatment with diazepam (46 children). The rates of respiratory depression with buccal 
midazolam and rectal diazepam were similar (3.0% and 3.3%, respectively). Compared 
to intravenous diazepam, intravenous lorazepam was associated with less respiratory 
depression. No child suffered respiratory depression associated with intravenous 
valproate treatment, compared to one child with intravenous phenobarbital. When 
looking at all adverse events, intravenous valproate was significantly safer than 
intravenous phenobarbital. Respiratory depression was not noted in children who 
received intravenous levetiracetam; however, all levetiracetam studies identified in this 
review were cohort and non-comparative. 
In conclusion, in the treatment of acute tonic-clonic seizures (including CSE), buccal 
was the best administration route for children admitted to the emergency department. 
Intravenous lorazepam treatment was associated with less respiratory depression than 
intravenous diazepam. Where IV access was practicable, intravenous lorazepam was the 
drug of choice. More randomised control trials are needed to evaluate the effectiveness 
and safety of AEDs as a second-line treatment.  
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CHAPTER 1: INTRODUCTION 
1. Background 
Status epilepticus (SE), and specifically convulsive status epilepticus (CSE) is a  
neurological emergency associated with a low, but definite mortality and significant 
morbidity; this applies to both adult and paediatric (<18 years)  populations[1].  
The earliest description of CSE was found in a series of medical texts known as Skikku 
(“all diseases”) on Babylonian clay tablets from the period between 1067 and 1046 B.C. 
[2]. In the fourth century BC, Hippocrates described a severe condition associated with 
prolonged seizures and concluded that death may occur from these seizures [3]. At the 
beginning of the 19
th
 century, systematic studies of epileptic seizures were started on 
hospitalised patients and led to the description of many types of seizures including CSE, 
which was known at that time as grand mal status or “etat de mal” [3]. The expression 
“status epilepticus” was first used in Bazire’s translation of Trousseau’s lectures in 
clinical medicine in 1868 and these lectures made it clear that CSE is a series of attacks 
rather than a single seizure with a different form [4]. 
1.1 Definition 
There are two broad categories of SE: convulsive status epilepticus (CSE) and non-
convulsive status epilepticus (non-CSE). The identification of non-CSE from 
behavioural signs is difficult and electroencephalography (EEG) is often a crucial 
diagnostic tool [5]. Therefore, this thesis will focus discussion on CSE. 
Most authors distinguish CSE from other types of seizure based on the duration of the 
attack. The International League Against Epilepsy (ILAE) standard definition is a single 
seizure or series of seizures lasting for 30 minutes or longer with unconsciousness 
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between seizures [6]. They suggest that the incidence of brain injury rises markedly 
after a 30-minute period and is almost certain after 60 minutes of continued CSE. This 
definition has been used widely for epidemiological and pathophysiological purposes 
[7, 8]. 
There are four phases of status epilepticus. They are classified on the basis of duration 
as follows[9-12]: 
1- Early phase or premonitory status: in which the convulsion continues for more 
than 5 minutes. At this stage the first line treatments (benzodiazepines) are used 
to control the seizure either prior to arrival at hospital, by the patient’s parents or 
paramedics, and at hospital in the emergency department. 
2- Established status epilepticus: in which the seizure activity continues for more 
than 10 and up to 30 minutes with loss of consciousness between seizures. In 
this stage second line treatments such as intravenous phenytoin, phenobarbital or 
levetiracetam are used to try and terminate it. This phase of status epilepticus 
may be termed  benzodiazepine-resistant status epilepticus. 
3- Refractory status epilepticus: in which the seizure activity (convulsion) lasts for 
more than 30 minutes or has failed at least one dose of benzodiazepine and a 
dose of second-line intravenous AED, or both.  
4- Super-refractory status epilepticus: in which the seizure activity lasts for more 
than 24 hrs and the patient will have been treated with intravenous anaesthetics 
such as thiopental, pentobarbital or propofol.  
1 Introduction 
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1.2 Classification 
The first classification of CSE was established in 1962 in Marseille [13]. The 
classification was based on the type of seizure: partial, generalised or unclassified. 
However, this classification was not useful in routine clinical practice. Moreover, it was 
unhelpful in failing to include the aetiology. Correspondingly, it was unhelpful in 
determining the treatment and outcome of CSE. 
In 1994, Shorvon introduced a new classification based on several factors: seizure type, 
age group, pathophysiological mechanisms and clinical features including EEG. This 
classification was more appropriate in clinical practice because it provided valuable 
information about prognosis and aetiology [14]. Shorvon further divided SE into four 
age-related categories: the neonatal period, infancy and childhood, childhood and 
adulthood. 
Mastrangelo and Celato in their 2012 review [15] categorised SE into CSE and non-
CSE (Table 1.2). 
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Table 1. 1: Status epilepticus classification 
Convulsive SE Non-convulsive SE 
 Focal 
 Focal motor 
 Focal motor with secondary 
generalization 
 Epilepsia partialis continua 
 Generalized 
 Myoclonic 
 Clonic 
 Tonic 
 Tonic-clonic 
 Absences (typical/atypical) 
 Focal status epilepticus with sensory 
symptoms 
 Autonomic or focal status epilepticus with 
affective symptoms 
 Focal status epilepticus with autonomic 
symptoms (Panayiotopoulos 
 syndrome) 
 Complex-partial status epilepticus 
 Continuous spike and wave during slow 
sleep 
This table is adapted from Mastrangelo and Celato [15] 
Non-CSE is not considered a medical emergency since patients do not lose 
consciousness and usually return to normal within minutes of its resolution (either 
spontaneously or in response to treatment). In CSE, however, early treatment is 
essential to avoid irreversible brain injury through both metabolic decompensation and 
respiratory depression which further exacerbates the cerebral metabolic injury through 
anoxia, and subsequently, profound hypotension [16].
 
1.3 Aetiology 
The formal aetiology of status epilepticus has been classified by the International 
League Against Epilepsy [17] into five divisions: acute symptomatic, remote 
symptomatic, idiopathic epilepsy-related, cryptogenic epilepsy-related and unclassified. 
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In 2006, the North London Convulsive Status Epilepticus in Childhood Surveillance 
Study (NLSTEPSS) classified the aetiology into 7 groups: prolonged febrile seizure, 
acute symptomatic, remote symptomatic, remote with acute causes, idiopathic epilepsy 
related, cryptogenic epilepsy related and unclassified (Table 1.3) [18]. 
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Table 1. 2: Aetiology of status epilepticus 
Aetiology Definition Causes 
Prolonged febrile seizure CSE that occurred in normal children who had no 
history of central nervous system (CNS) infection 
and aged between 6 months and 5 years with a 
temperature at least 38.0C 
Febrile seizure 
Acute symptomatic CSE that occurred in otherwise healthy children 
who had neurological insult within the past week 
Meningitis 
Viral CNS infection 
Head injury 
Hypoxia 
Remote symptomatic CSE reported in children who had a pre-existing 
CNS abnormality for more than 1 week  
Tuberous sclerosis 
Encephalopathy 
Remote with acute causes CSE that occurred in children within a week from 
febrile illness or acute neurological insult and 
associated with a history of previous neurological 
abnormalities  
Cerebral palsy  
Hydrocephalus 
Idiopathic epilepsy related CSE that occurred in children who had a history 
of idiopathic epilepsy with no symptomatic 
causes for the seizure  
Idiopathic epilepsy 
Cryptogenic epilepsy related CSE that occurred in children who had a history 
of cryptogenic epilepsy with no symptomatic 
causes for the seizure 
Cryptogenic epilepsy 
Unclassified All other SE -------- 
This table is adapted from Chine et al [18] 
1.4 Epidemiology 
The incidence of CSE in children ranges from 10 to 38 in 100,000 per year [18-20]. The 
higher incidence is reported in children aged less than 4 years [21] and is most common 
in children aged less than one year. The risk decreases in the teenage years[22]. 
Children with a history of pre-existing epilepsy constitute the highest proportion of SE 
patients (10-20%) [23, 24]. Febrile SE was most commonly documented in children less 
than 2 years old while cryptogenic and symptomatic SE were more frequently 
documented in older children [25]. In the NLSTEPSS study, prolonged febrile SE was 
the cause of first episodes of CSE in 32% of children; idiopathic epilepsy-related SE 
was identified in 10% of paediatric cases and cryptogenic epilepsy in 2% [18]. 
 
1 Introduction 
 
18 
 
1.5 Treatment 
Current treatment protocols for CSE are designed to terminate  the seizure and maintain 
vital functions [26] as rapidly and as safely as possible. International organisations and 
institutions follow different guidelines and algorithms based on local experience and the 
availability of anti-epileptic drugs (AEDs) [27-36], but all recommend starting 
treatment early to avoid brain injury [26]. Traditionally and almost universally, 
treatment is instituted if the episode of CSE has not stopped after 5 minutes; the 
rationale for this is that over 90% of convulsive seizures will stop spontaneously after 3-
4 minutes and if the seizure has not stopped after 4-5 minutes, it is highly unlikely to 
then stop spontaneously. In addition, the longer the duration of the presenting 
convulsive seizure, the more difficult it will be to terminate with AEDs. In the UK, the 
Status Epilepticus Working Group recommended a CSE protocol for children based on 
a comprehensive literature review and consequent consensus among its expert group 
[32]. The experts included Consultants in General Paediatrics, Paediatric Accident and 
Emergency Medicine, Paediatric Pharmacology and Paediatric Neurology. This 
guideline was adopted by the National Institute for Health and Care Excellence (NICE, 
2004) [37], the Scottish Intercollegiate Guidelines Network (SIGN, 2005) [34] and is 
used in the Advanced Pediatric Life Support (APLS) course [38] (Figure 1.4). In 2012, 
the revised Epilepsy Guideline published by NICE indicated that rectal paraldehyde 
should no longer be considered as a definite, but only as an optional treatment in the 
management algorithm, depending on the policy of each local Emergency Department 
or Emergency Room [33]. In part this change reflected the concern that paraldehyde 
might have contributed to the incidence of respiratory depression observed in the 
NLSTEPSS Study [18]. 
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Figure 1. 1: Drug management protocol for CSE in the UK 
 
This diagram is adopted from Appleton et al [32] 
All international guidelines recommend intravenous (IV) short-acting benzodiazepine as 
a bolus and then a second dose if the seizure is not terminated. In the UK[33] , Canada 
[39] and US [35] intravenous lorazepam is the preferred treatment for CSE if IV access 
is already available or obtained immediately on arrival in the Emergency Department / 
Room. In France, clonazepam is the preferred first treatment if IV access is obtained 
[40]. Phenytoin and phenobarbital (long-acting AEDs) are the second-line treatments 
used in the UK. Howevr, phenobarbital may be associated with a higher risk of 
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hypotension and respiratory depression than phenytoin [32]. Early studies suggested 
that IV phenobarbital had comparable anticonvulsant activity to IV phenytoin; however, 
an increased incidence of respiratory depression has been reported, particularly when 
phenobarbital was administered in combination with a benzodiazepine [41-45]. 
Fosphenytoin is the preferred second-line AED in the US [35], Canada [39] and France 
[40]. There are two significant advantages in using fosphenytoin over phenytoin:  first, 
it can be given intramuscularly and second, it can be infused slightly more rapidly than 
phenytoin[46]. However, one randomised study reported that fosphenytoin and 
phenytoin showed a similar frequency of adverse side-effects[47]. Fosphenytoin is 
usually prescribed as ‘phenytoin-equivalents’ and this may result in dose-miscalculation 
and consequent dosing-errors. Finally, fosphenytoin is considerably more expensive 
than phenytoin (at least four to five times more expensive in the UK) and is not 
considered to be cost-effective when compared with phenytoin.[47, 48]. For these 
reasons, fosphenytoin is not currently prescribed in the UK. It is possible that other 
AEDs, and specifically levetiracetam or sodium valproate may replace phenytoin in the 
future [49]. However, sodium valproate may  be associated with serious adverse events, 
particularly hepatotoxicity and pancreatitis[50]. Several studies have recommended 
levetiracetam instead of sodium valproate or phenytoin as a second-line treatment 
following the failure of benzodiazepines [51-55].  
A current study entitled EmergenCy Treatment with LevetIracetam or Phenytoin in 
Status Epilepticus (‘EcLiPSE’) in children – an open-label randomised controlled trial 
has been approved by the North West - Liverpool Central Research Ethics Committee in 
the UK. This is an NIHR HTA-funded study which will be conducted in approximately 
25-30 Accident and Emergency Departments (Emergency Rooms) throughout the UK. 
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Children aged between 6 months and <18 years with focal or generalised CSE which 
has failed to respond to first-line treatment (typically, one or two doses of a 
benzodiazepine) [56]. The children will be randomly selected for treatment with either 
intravenous levetiracetam (40 mg/kg administered over 5 minutes) or intravenous 
phenytoin (20mg/kg infused) administered over 20 minutes. The aim of the study is to 
evaluate whether levetiracetam is more effective than phenytoin as a second-line 
emergency antiepileptic drug, and to compare their adverse side effects. The study is 
ongoing and the results are expected to be published in late 2019.   
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1.6  The Research Aims 
Children with CSE are at high risk of mortality and also morbidity. As this is a medical 
emergency, the management of CSE must be rapid, effective and safe. Consequently, 
there is a risk that the treatment of CSE may be associated with iatrogenic 
complications, including potentially serious adverse side-effects.  Despite the fact that 
much research has been carried out to assess the effectiveness and safety in adult 
patients, less research has been done to evaluate this in infants, children and young 
people. 
This research was designed to assess the effectiveness and safety of 1
st
 and 2
nd
 line 
treatment of acute tonic clonic status epilepticus in children. This was achieved through 
two systematic reviews and meta-analyses namely: 
1. A systematic review of the effectiveness of 1st and 2nd line treatment of 
acute tonic clonic status epilepticus in children. The effectiveness of the 
following AEDs were evaluated; benzodiazepines, paraldehyde, 
phenytoin, phenobarbital, sodium valproate and levetiracetam (Chapter 
3). 
2. A systematic review of the safety of AEDs in children who received 
benzodiazepines, paraldehyde, phenytoin, phenobarbital, sodium 
valproate and levetiracetam, in the treatment of acute tonic clonic status 
epilepticus (Chapter 4) 
 
2 Methods 
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CHAPTER 2: METHODS 
2.1 Introduction 
For this thesis I have conducted two systematic reviews in the paediatric population; the 
effectiveness of AEDs for convulsive status epilepticus (CSE) (chapter 3) and the 
safety of AEDs for convulsive status epilepticus (CSE) (chapter 4). 
Systematic reviews are the gold standard for evaluating valuable scientific evidence in 
health care, they play a major role in helping practitioners develop guidelines and 
improve health care [57]. The key points of systematic reviews are that they include a 
clear objective and eligible criteria and have a rigorous methodology that attempts to 
identify all relevant studies of high quality to answer the question posed [58]. 
2.2 Objectives 
a) To compare the effectiveness of AEDs for convulsive status epilepticus (CSE) 
(chapter 3) 
b) To compare the safety of AEDs for convulsive status epilepticus (CSE) (chapter 
4). 
The primary and secondary objectives are outlined in the respective chapters. 
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2.3  Search strategy and eligibility criteria 
Six electronic databases were searched in these studies, namely the ; US National 
Library of Medicine’s bibliographic database (MEDLINE), Excerpta Medica Database 
(EMBASE), International Pharmaceutical Abstract (IPA), Cumulative Index to Nursing 
and Allied Health Literature (CINHAL), Cochrane database, and PubMed. All scientific 
papers involving children aged up to 18 years were included. 
MEDLINE, EMBASE and IPA were searched separately and then combined to remove 
duplications. While Cochrane, CINHAL and Pubmed were not combined with previous 
databases, both were searched and reviewed manually to remove duplications and 
identify relevant articles. The search strategy included all languages. Foreign language 
publications were translated to English (were translated where possible) and then the 
applicable data were extracted for analysis. 
The types of studies, the types of participants, the types of interventions and the types of 
outcome measures were the main four criteria identified for selecting the scientific 
papers that included and analysed in these systematic reviews.  
The following subsections will describe in detail the search strategy and eligibility 
criteria for each systematic review. 
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2.3.1 The effectiveness of AEDs for convulsive status epilepticus (chapter 4) 
2.3.1.1 Databases and search terms  
A literature search was conducted electronically on MEDLINE (1946-April 2015), 
EMBASE (1974-April 2015), Cochrane database (until April 2015) and Pubmed 
database (until April 2015). The search terms were selected based on their sensitivity 
and specificity according to the previous systematic reviews available [59]. The search 
terms used are shown table 2.1. 
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Table 2. 1: Search strategy for Ovid database (EMBASE AND MEDLINE) 
 Subject Result          Search type 
1 epilep$.tw. 241072 Advance 
2 seizure$.tw. 213878 Advance 
3 convulsion$.tw. 35265 Advance 
4 exp Epilepsy/ 317612 Advance 
5 exp Seizures/ 153216 Advance 
6 1 or 2 or 3 or 4or 5 467656 Advance 
7 exp Epilepsy, Tonic-Clonic/ 7715 Advance 
8 tonic clonic.tw. 11598 Advance 
9 status epilepticus.tw. 20675 Advance 
10 exp Status Epilepticus/ 21427 Advance 
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 467731 Advance 
12 limit 25 to human 341377 Advance 
13 (pediatr$ or paediatr$).tw. 562824 Advance 
14 child$.tw. 2273156 Advance 
15 exp child/ or exp child, preschool/ or exp infant/ 4239990 Advance 
16 13 or 14 or 15 4922336 Advance 
17 12 and 16 8869 Advance 
18 emergency.tw. 383850 Advance 
19 17 and 18 267 Advance 
20 benzodiazepines.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, 
ui, sh, tn, dm, mf, dv, kw] 
49227 Advance 
21 paraldehyde.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sh, 
tn, dm, mf, dv, kw] 
1907 Advance 
22 phenytoin.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sh, 
tn, dm, mf, dv, kw] 
74297 Advance 
23 phenobarbital.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, 
sh, tn, dm, mf, dv, kw] 
83492 Advance 
24 levetiracetam.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, 
sh, tn, dm, mf, dv, kw] 
6139 Advance 
25 sodium valproate.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, 
ui, sh, tn, dm, mf, dv, kw] 
5985 Advance 
26 valproic acid.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, 
sh, tn, dm, mf, dv, kw] 
62631 Advance 
27 20 or 21 or 22 or 23 or 24 or 25 or 26 227607 Advance 
28 19 and 27 620 Advance 
29 remove duplicates from 28 490 Advance 
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2.3.1.2 Inclusion and Exclusion criteria  
The inclusion criteria were: 
1) Randomised controlled studies (blinded or unblinded) or non-randomised 
controlled studies (prospective hospital based studies and retrospective 
population based studies).  
2) Studies that evaluated the efficacy of the following antiepileptic drugs; 
benzodiazepines, phenytoin, phenobarbital, phenytoin, sodium valproate, 
paraldehyde and levetiracetam irrespective of route of administration.  
3) Children aged ≤18 years admitted to hospital or emergency department with 
acute tonic-clonic convulsion.  
We excluded case reports from the effectiveness analysis because it was impossible to 
determine the response rate from individual cases. Also, we excluded reviews, 
comments, letters, correspondence and short surveys, adult studies (aged over 18 years) 
and studies where the number of children or the data for children were not separately 
described. 
2.3.1.3 Outcome measures 
 The termination of acute tonic clonic seizures following treatment. 
  The seizure recurrence rate from the termination of convulsion.  
 Time to seizure control after drug administration. 
 The need for additional dose(s). 
 Additional antiepileptic drugs. 
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2.3.1.4 Data extraction  
All analysed articles were read carefully and the following types of data were extracted: 
 Year of publication 
 Study region 
 Study period 
 Age of children  
 Number of children receiving AEDs 
 Route of administration  
 Doses of AEDs 
 Successful seizure control rate  
 Time to seizure control after administration the medications  
 Seizure recurrence rate  
 Number of children who needed of second dose and/or additional AEDs 
2.3.1.5 Quality assessments 
The quality of RCTs (for meta-analysis) was assessed for risk of bias.  Randomised 
controlled trials were assessed using the Cochrane risk of bias checklist [58]. For RCTs 
to be considered as having a low risk of bias, the rating should be ≥ 4 out of 7 marks. 
The qualities of prospective observational and retrospective population based studies 
were assessed using a STROBE checklist [60]. Any study with a minimum score of 
50% was considered a good quality study. Two independent assessors (KA and research 
nurse JA) blinded to each other’s scores assessed each paper, and a further paediatric 
clinical pharmacologist (Dr Sammons) independently resolved any disputes between the 
independent blinded reviewers. 
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2.3.1.6 Statistical analysis 
A descriptive analysis for the number and age of children receiving each medication, 
the number of children who successfully controlled their seizure, time to seizure control 
after antiepileptic administration, the seizure recurrence rate and the need for a second 
dose and/or additional antiepileptic drugs to terminate the convulsion was conducted 
using SPSS version 12 statistical software. This measured the median, ranges and 
Interquartile range (IQR). The meta-analysis was performed using RevMan software 
version 5.3 and forest plots used to compare the effectiveness data between the AEDs. 
The relative ratio (RR) of effectiveness was calculated and 95% CI was determined. 
The heterogeneity (I
2
) was assessed between studies by using Chi-squared (X
2
) test 
when p-value were less than 0.05[58]. A random effect model was used for pooled data 
if heterogeneity (I
2
) exists (≥ 50%). However, a fixed effect model was used for pooled 
data if heterogeneity (I
2
) did not exist (< 50%). The differences between treatments was 
considered significant at p<0.05. 
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2.3.2 The toxicity of AEDs for convulsive status epilepticus (CSE) (chapter 5) 
2.3.2.1 Databases and search terms  
We used the same databases and search terms described previously for the effectiveness 
systematic review (section 2.3.1.1, table 2.1.) 
2.3.2.2 Inclusion and Exclusion criteria 
The inclusion criteria were the same as for effectiveness of AEDs for CSE. However, 
case reports and retrospective population based studies were also included to provide a 
complete picture of all AEs documented in the literature. 
The exclusion criteria were reviews, comments, letters, correspondence and short 
surveys, adult studies (aged over 18 years) and studies where the number of children or 
the data for children were not described separately. 
2.3.2.3 Outcome measures 
 The incidence of adverse effects. 
 The incidence of admission to the ICU.  
 Death due to the adverse effects. 
2.3.2.4 Data extractions  
All analysed articles were read carefully and the following types of data were extracted: 
 Year of publication 
 Study region 
 Study period 
 Age of children  
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 Number of children receiving AEDs 
 Route of administration  
 AEDs doses  
 Number of children experiencing adverse events  
 Adverse events classification (Adverse events were classified according to 
the recommendation of the National Cancer Institute in the US (NCI) [61] 
 ICU admissions and death cases related to adverse effects  
2.3.2.5 Quality assessments 
We used the same quality assessments tools for RCTs, prospective observational and 
retrospective population based studies described in the previous chapter (section 
2.3.2.5) 
2.3.2.6 Statistical analysis 
A descriptive analysis for the number and age of children receiving each medication, 
the reported numbers of adverse events, ICU admissions and deaths due to adverse 
events of the AEDs was conducted by using SPSS version 12 statistical software to 
measure the median, ranges and Interquartile range (IQR). The risk per 100 children 
was calculated from RCTs and cohort studies (both hospital and population) by dividing 
the number of children with adverse events by the total number of children receiving 
diazepam or midazolam or lorazepam or phenobarbital or phenytoin or levetiracetam or 
sodium valproate or  paraldehyde (after combining all AEs from these study types). 
 For statistical analysis, a meta-analysis was performed using RevMan software version 
5.3 and forest plots used to compare the safety data between diazepam, midazolam, 
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lorazepam, phenobarbital, phenytoin, levetiracetam, sodium valproate and paraldehyde. 
Relative risk of the safety was calculated and 95% CI were determined. The 
heterogeneity (I
2
) was assessed between studies by using a Chi-squared (X
2
) test when 
p-value were less than 0.05[58]. A random effect model was used for pooled data if 
heterogeneity (I
2
) existed (≥ 50%). However, a fixed effect model was used for pooled 
data when heterogeneity (I
2
) did not exist (< 50%). The differences between treatments 
was considered significant at p<0.05. Also, a Fisher’s exact test was used to compare 
the respiratory depression between the two most common AEDs. Values of p<0.05 were 
considered significant.  
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CHAPTER 3: SYSTEMATIC REVIEW ONE 
3.1 Introduction 
Status epilepticus is an emergency condition, with associated mortality and morbidity, 
and requires prompt and effective treatment. The definition for generalised convulsive 
tonic-clonic status epilepticus is seizures lasting for 30 minutes or more associated with 
loss of consciousness [62, 63]. However, effective management of acute tonic-clonic 
seizures should be given to all patients whose seizures have lasted ≥ 5 minutes and 
certainly those who attend emergency department, regardless of the duration of 
convulsion, to prevent progression to refractory or super refractory status epilepticus 
[59]. 
Benzodiazepines such as midazolam, lorazepam and diazepam are the first-line 
treatment for children with acute tonic-clonic seizures [38]. When benzodiazepines fail 
to stop convulsions, after a second dose, an alternative anticonvulsant should be given 
such as rectal paraldehyde, intravenous or intraosseous phenytoin, or intravenous or 
intraosseous phenobarbital. Other agents have also been explored; an open-label study 
showed that sodium valproate was more effective than phenytoin and phenobarbital for 
second-line treatment [64]. In 2012, an observational study showed that levetiracetam 
seemed to be effective and safe in the treatment of CSE [51].  
The primary aim of this review was to evaluate the effectiveness of the following 
antiepileptic drugs: benzodiazepines, paraldehyde, phenobarbital, phenytoin, sodium 
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valproate, and levetiracetam, irrespective of the administration routes, for the treatment 
of acute tonic-clonic seizures including convulsive status epilepticus in children. 
3.2 Methods 
The methodology adopted in this review was described in chapter 2. 
3.3 Results 
1,851 articles were evaluated based on the specified inclusion and exclusion criteria 
(Figure 3.1 and Table 3.1). Twenty studies were identified and analysed. In addition, 8 
studies identified by the search were published in Turkish and Japanese, it was not 
possible to translate them for further assessment for inclusion. (Figure 3.1 and Table 
3.1). 
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Figure 3. 1: Flow chart for the systematic review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EMBASE = 475 
 
MEDLINE = 145 
 
PUBMED = 1343 
Total publications after limiting to human subjects = 1981 
1851 articles 
 
Duplication = 130 
 
40 articles 
1268 Abstracts not meeting 
inclusion criteria 
543 Review articles, 
conference, survey and letter 
 
21 articles excluded: 
9 non-comparative studies 
8 articles published in 
Japanese (5) &Turkish (3)  
3 with data for not 
separately described  
1 case report 
1811 articles excluded after 
screening abstracts 
20 STUDIES INCLUDED 
COCHRANE = 18 
1 article added by 
manual search 
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Table 3. 1: Reasons for exclusion from the systematic review 
Reason Total 
Irrelevant article 1268 
Review, conference, survey 543 
Non-comparative studies 9 
Studies in Turkish and Japanese  8 
Studies reporting the efficacy without mentioning the number of 
children, or the data for children not described separately. 
3 
Case report 1 
Total 1832 
 
3.3.1. Quality assessment 
The 20 studies that remained after screening were assessed; 17 RCTs with the Cochrane 
risk of bias tool [58] and three observational studies (comparative non-randomised 
studies) with the STROBE tool [60]. Eight RCTs were rated low-risk for all criteria [65-
72]. The method of randomisation was inadequately described in 4 studies [73-76], and 
was unclear in one study [77]. In 3 RCTs, the risk of bias in the allocation concealment 
was high [73, 76, 78]. One RCT was rated high-risk in blinding of participants and 
personnel [78] (Figure 3.2). None of these RCTs were excluded from the systematic 
review. None of the observational studies (comparative non-randomised studies) were 
excluded as all studies were of sufficiently good quality. 
 
 
3 The Effectiveness of AEDs for convulsive status epilepticus (CSE) 
 
37 
 
Figure 3. 2 Risk of bias summary 
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3.3.2. The study descriptions 
Twenty studies were included; 17 were randomised controlled trials [65-81] and 3 were 
comparative non-randomised studies [82-84]. These studies involved more than 3,000 
children aged from birth to 18 years. Most of the children were treated with lorazepam 
(1503, 47%) and diazepam (1041, 32%) (Table 3.2). 
Table 3. 2: Antiepileptic drugs used in 20 studies 
Anti-epileptic drug used 
No. of studies 
(N =20)
* 
No. of children 
(N = 3178)
* 
Lorazepam 8 1503 
Diazepam 15 1041 
Midazolam 8 416 
Diazepam + phenytoin 1 88 
Paraldehyde 1 80 
Sodium valproate 2 52 
Phenobarbital 2 41 
Phenytoin 2 26 
Phenobarbital + phenytoin 1 7 
Other benzodiazepine not specified 1 7 
* Some children and studies accounted more than once. 
3.3.2.1 Randomised controlled studies  
17 randomised controlled trials published between 1995 and 2015 were analysed, 
including 11 open-label studies [66, 69, 71-74, 76-79, 81], 4 single-blind studies [65, 68, 
75, 80], and 2 double-blind studies [67, 70]. Of these 17 studies; 15 were 2-armed 
clinical trials, one was 3 arms [71] and the remaining study had 4 arms [76]. 8 studies 
compared midazolam and diazepam (Table 3.3). 
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Table 3. 3: Randomised controlled studies characteristics 
Study characteristics No. of studies 
(N = 17) 
No. of children 
(N = 3047)
 
Type of blinding   
Open label 11 1796 
Single blinded 4  918 
Double blinded 2  333 
Antiepileptic drugs compared   
A. Midazolam vs. diazepam 8 914 
B. Lorazepam vs. diazepam 3 795 
C. Lorazepam vs. paraldehyde 1 160 
D. Lorazepam vs. diazepam + phenytoin 1 178 
E. Intravenous lorazepam  vs. intranasal lorazepam  1 141 
F. Intravenous lorazepam  vs. intranasal & buccal LZP 1 761 
G. Sodium valproate vs. phenytoin 1  38 
H. Sodium valproate vs. phenobarbital 1  60 
 
Sixteen of the 17 randomised control trials included were conducted solely in the 
paediatric population. In the single mixed-population study, the rate of successful 
seizure control was described separately for the children [77]. The successful seizure-
control rate was documented in all 17 RCTs studies. Twelve studies also documented 
the seizure recurrence rate (Table 3.4). 
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Table 3. 4 : Outcomes  
Study characteristics No. of studies 
(N = 17)
* 
Successful seizure control 17 
Time to seizure control 16 
Second dose or additional antiepileptic drugs 14 
Seizure recurrence rate  12 
* Some studies accounted more than once. 
The definition of  acute tonic-clonic seizures including convulsive status epilepticus 
varied among studies; nine [65, 67, 70-72, 75, 77, 79, 81] used a definition of at least 5 
minutes of continuous seizure, while one study [66] used a definition of at least 10 
minutes. Seven studies did not specify the definition [68, 69, 73, 74, 76, 78, 80]. 
The definition of effectiveness of the intervention also varied between studies. The time 
to seizure control was the sole measure for determining successful treatment in 11 
studies; in 8 of these treatment was considered effective if the seizure was controlled 
within 10 minutes of drug infusion [66, 69-75]. In 2 studies, the criteria was 5 minutes 
[68, 80], and one study used an 8-minute definition [76]. The other 6 studies used some 
combination of a time frame along with recurrence rate and incidence of respiratory 
depression and hypotension. In 3 of these studies, the treatment was considered 
successful if the seizure was controlled within 30 minutes, without recurrence within 1 
hour, and without respiratory depression [65, 78, 79]. In one study, the criteria were 
described as control of seizure within 20 minutes, no recurrence within 1 hour and no 
incidence respiratory depression or hypotension [67]. Another study defined 
effectiveness as seizure control within 20 minutes and no recurrence within 12 hours 
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[77]. In the remaining study, the criteria were defined as control within 10 minutes and 
no recurrence within 30 minutes [81].  
The measurement of seizure recurrence also varied among studies. In 6 studies, it was 
measured for one hour [65, 66, 69, 70, 78, 79], in 5 for 24 hours [67, 71, 72, 75, 76] and 
in one study for 18 hours [81]. The remaining 5 studies did not define recurrence [68, 
73, 74, 77, 80]. 
A. Midazolam versus diazepam 
Eight studies compared the effectiveness of midazolam and diazepam. They involved 
more than 900 children (466 treated with midazolam) aged between birth and 14 years. 
Five were open-label [66, 73, 74, 78, 79] and 3 were single-blind [65, 68, 80]. The 
effectiveness of buccal midazolam was compared with rectal diazepam in 4 studies [65, 
73, 78, 79] and with intravenous diazepam in one study [80]. Of the remaining 3 studies, 
2 compared the effectiveness of intranasal midazolam with intravenous diazepam [66, 
74], and the third compared the effectiveness of intramuscular midazolam with 
intravenous diazepam [68]. 
A.1. Buccal midazolam versus rectal diazepam 
The following 4 studies compared buccal midazolam to rectal diazepam in more than 
600 children aged between birth and 15 years. Three were open-label [73, 78, 79] and 
one was single-blinded [65]. 
McIntyre et al. (2005) conducted a 3-year, multicentre, randomised, controlled, open-
label study in children who attended an emergency department with active convulsions 
in the UK [78]. The study medications were selected in weekly blocks at 4 hospitals. 
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Children were excluded if they presented with partial seizures or non-convulsive status 
epilepticus. A total of 219 episodes in 177 children were evaluated. The treatment was 
considered successful if the seizures were controlled within 10 minutes of the initial 
dose, with no recurrence within one hour and no respiratory depression. A local 
protocol was applied if the seizure lasted more than 10 minutes after the initial dose. 
Results were reported separately for the initial episode and the total episodes.  
Baysun et al. (2005) performed a prospective, single-centre study in Turkey involving 
43 children aged between 2 months and 12 years with acute tonic-clonic seizures [73]. 
Randomisation was achieved by alternating the study medications daily. Treatment was 
recorded as successful if the seizure terminated within 10 minutes of the initial dose. If 
seizures were still active after 10 minutes, crossover treatment was applied: diazepam 
for the midazolam group and midazolam for the diazepam group. 
Mpimbaza et al. (2008) assessed buccal midazolam against rectal diazepam in 330 
children, aged between 3 months and 12 years, who attended an emergency department 
with prolonged seizures [65]. This was an 8-month, single-blind, single-centre study in 
Uganda. Randomisation was performed by an independent staff member who used 
computer-generated treatment codes and opaque envelopes. Treatment was deemed 
successful if the seizures stopped within 10 minutes after the initial dose, without 
recurrence for one hour. If the seizure remained active for more than one hour, 
intravenous diazepam was given. This study also assessed respiratory depression. 
Children were excluded if they had received intravenous phenobarbital or intravenous 
diazepam within 24 hours prior to admission. 
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Ashrafi et al. (2010) conducted a one-year, open-label, randomised study in 2 paediatric 
referral hospitals in Iran on 98 children aged less than 12 years who attended the 
emergency room with acute convulsive seizures lasting for more than 5 minutes [79]. 
Half the children were selected to receive buccal midazolam via a random number table. 
The treatment was considered successful if the seizures were controlled within 5 
minutes of the initial dose, with no respiratory depression or recurrence of seizure for 
one hour. If the seizure remained active or recurred within one hour after the initial dose, 
intravenous diazepam was given.  
Overall, the seizure terminated in 231 of 329 children (70%) who received buccal 
midazolam and in 175 of 319 children (55%) who received rectal diazepam. Seizure 
termination was higher with buccal midazolam in 3 of the studies (Table 3.5). Diazepam 
was more effective  in one small study in Turkey, however this was not statistically 
significant (p = 0.57) [73]. The pooled risk ratio of the outcomes of these 4 studies 
showed that the effectiveness of buccal midazolam in seizure termination was superior 
to that of rectal diazepam (RR: 1.29; 95% CI: 1.15 to 1.44; p < 0.04). 
Seizure termination occurred 3 to 10 minutes after treatment with buccal midazolam, 
and 3 to 15 minutes after rectal diazepam.  
No children in either group needed additional doses of the same drugs. However, 3 of 
the studies showed that 88 of 280 children (31%) who received buccal midazolam 
required additional antiepileptic drugs (AEDs) to terminate their seizures compared to 
121 of 270 children (45%) who received rectal diazepam [65, 73, 78]; the difference 
was significant (RR: 0.7; 95% CI: 0.57 to 0.87; p = 0.001). 
3 The Effectiveness of AEDs for convulsive status epilepticus (CSE) 
 
44 
 
The seizure recurrence rate was reported in 2 of the studies [65, 78].  Seizures recurred 
in 17 of 257 children (7%) who received buccal midazolam and in 32 of 250 children 
(13%) who received rectal diazepam; the difference was significant (RR: 0.51; 95% CI: 
0.29 to 0.9; p = 0.02) (Table 3.5).  
In summary, buccal midazolam is superior to rectal diazepam for the treatment of acute 
seizures in children. It is more effective and associated with a lower recurrence rate of 
seizures (Table 3.5 and Figure 3.3). 
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Table 3. 5: Buccal midazolam versus rectal diazepam  
Reference, 
country  
Study 
design  
Age (Y) No. of 
children  
AEDs Dose (mg/kg) Seizure control 
(No. of children) 
RR (95% CI)  
P-value 
 
 
MDZ              DZP 
Time to seizure control (No. of children) 
 
 
 
 
 
MDZ                                          DZP 
Additional AEDs     
(No. of children) 
RR (95% CI) 
P-value 
 
 
MDZ                      DZP 
Recurrence rate* 
(No. of children) 
RR (95% CI) 
P-value 
 
 
MDZ                        DZP 
McIntyre et 
al., 2005, 
UK [78] 
Open label 
RCT 
0.7-15 92  
 
85  
MDZ  
 
DZP  
0.5 BUC 
 
0.5 PR 
49                         24 
 
1.89 (1.3-2.8) 
p = 0.001 
Median 8 min                     Median 15 min 33                                47 
 
0.65 (0.46-0.91) 
p = 0.01 
7                                    12 
 
0.54 (0.2-1.3) 
p = 0.17 
Baysun et 
al., 2005, 
Turkey [73] 
Open label 
RCT 
0.2-12  23  
 
20 
MDZ  
 
DZP  
0.25 BUC 
 
0.3-0.5 PR 
18                         17 
 
0.92 (0.7-1.2) 
p = 0.57 
3 min (12)                               3min (10) 
 
3-5 min (3)                              3-5 min (4) 
 
5-10 min (3)                            5-10 min (3) 
5                                    3 
 
0.45 (0.4-5.3) 
p = 0.58 
Data was not available 
Mpimbaza et 
al. 2008, 
Uganda [65] 
Single blind 
RCT 
0.3- 12  
 
165  
 
165  
MDZ  
 
DZP 
0.5 BUC 
 
0.5 PR 
115                       94 
 
1.22 (1-1.4) 
p = 0.02 
Median 4.7 min                  Median 4.3 
min 
  
 
50                                71 
 
0.7 (0.53-0.9) 
p = 0.02 
10                                  20 
 
0.5 (0.24-1) 
p = 0.06 
Ashrafi et 
al., 2010, 
Iran [79] 
Open label 
RCT 
0-12 49 
 
49 
MDZ  
 
DZP  
0.3-0.5 BUC 
 
0.5 PR 
49                         40 
 
1.22 (1.1-1.4) 
p = 0.004 
Median 4 min                       Median 5 min Data was not available 0                                      0 
Total 4 0-15 329 
 
319 
MDZ  
 
DZP  
0.25-0.5 BUC 
 
0.3-0.5 PR 
231                     175 
 
1.23 (1.01 - 1.5)      
p < 0.04 
3-10 min                                       3-15 min 88                              121 
 
0.7 (0.5-0.8) 
 p = 0.001 
17                                   32 
 
0.51(0.29-0.9) 
p = 0.02 
MDZ: Midazolam, DZP: Diazepam   
*  Within one hour 
** Median 
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Figure 3. 3: The effectiveness of buccal midazolam versus rectal diazepam  
1. Successful seizure control 
 
2. Additional AEDs 
 
3. Seizure recurrence 
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A.2. Intranasal midazolam versus intravenous diazepam 
There were 2 single-centre open-label studies that involved 114 children, aged between 
0.2 to 15 years [66, 74]. 
Lahat et al. (2000) performed a 12-month, single-centre, open-label, randomised study 
in Israel to compare intranasal midazolam with intravenous diazepam for treating febrile 
seizures [66]. It involved 44 children aged between 6 months and 5 years. Twenty-one 
children with 26 episodes were given intranasal midazolam, while 23 children with 26 
episodes were given intravenous diazepam. Patients were excluded if they had received 
AEDs or had an intravenous line established by paramedics prior to being admitted to 
the emergency room. Randomisation was performed by a hospital pharmacist (who was 
not involved in the study) via a number table and opaque, sealed envelopes. Treatment 
was considered effective if the seizures were controlled within 5 minutes, or successful 
but delayed if the seizures stopped between 5 and 10 minutes. For treatment failure 
(continued seizure more than 10 minutes after study medication was administered) the 
local treatment protocol was used. 
Four years later, Mahmoudian et al. (2004) assessed intranasal midazolam against 
intravenous diazepam in  70 children aged between 2 months and 15 years, who 
attended an emergency department with convulsive status epilepticus (CSE) [74]. This 
was a 14-month, single-centre, open-label, randomised study conducted in Iran. Patients 
were excluded if they had received prior emergency AEDs. Randomisation was 
allocated based on an odd-and-even number table (children with odd numbers received 
intravenous diazepam, and children with even numbers received intranasal lorazepam). 
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Treatment was considered successful if the seizure stopped within 10 minutes of initial 
study medication. For treatment failure (continued seizure after 10 minutes), 
intravenous diazepam was prescribed for the midazolam group and phenobarbital for 
the diazepam group.  
The seizure ended in 58 children (95%) who received the intranasal midazolam and in 
59 children (97%) who received intravenous diazepam; the difference was not 
significant (RR: 0.98; 95% CI: 0.91 to 1.06; p = 0.67). The rate of seizure termination 
was the same in the Iranian study [74]. There was a non-statistically significant 
difference in seizure termination  in the other study [66], with diazepam having the 
higher termination rate (Table 3.6). 
Seizure termination occurred 2.5 to 3 minutes after treatment with intranasal midazolam 
and 2.5 to 2.6 minutes after intravenous diazepam. 
The administration of additional antiepileptic drugs to terminate the seizures was 
reported only in the Lahat study. Three of 21 children (14%) who received intranasal 
midazolam needed additional antiepileptic drugs compared to 2 of 23 children (9%) 
who received intravenous diazepam; the difference was not significant (RR: 1.64; 95% 
CI: 0.3 to 8.9; p = 0.56)[66]. 
Neither study in this section recorded whether additional doses were required. 
The seizure recurrence rate was also only reported in the Lahat study; it was 5% (one 
child) for intranasal midazolam and 4% (one child) for intravenous diazepam [66]; the 
difference was not significant (RR; 1.1; 95% CI: 0.07 to 16.4; p = 0.95) (Table 4.6).  
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In conclusion, from these two small studies we can conclude that intranasal midazolam 
and intravenous diazepam were equally effective (Table 3.6 and Figure 3.4).  
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Table 3. 6: Intranasal midazolam vs. intravenous diazepam  
Reference, 
country  
Study 
design  
Age 
(Y) 
No. of 
children  
AEDs Dose 
(mg/kg) 
Seizure control 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
MDZ            DZP 
Time to seizure control  
 
 
RR (95% CI)  
P-value 
 
 
MDZ                                     DZP 
Additional AEDs 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
MDZ                  DZP 
Recurrence rate*  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
MDZ            DZP 
Lahat et al., 
2000, Israel 
[66]  
Open 
label 
RCT 
0.6-12  21  
(26 episodes) 
 
23  
(26 episodes) 
MDZ 
 
 
DZP 
0.2 (IN) 
 
 
0.3 (IV) 
23                        24 
 
0.96 (0.8-1.1) 
p = 0.64 
Mean 3.1 min               Mean 2.5 min 3                                2 
 
1.64 (0.3-8.8) 
p = 0.56 
1                         1 
 
1.1 (0.07-16.4) 
p = 0.95 
Mahmoudian 
and Zadeh,  
Mohammadi, 
2004, Iran 
[74] 
Open 
label 
RCT 
0.2-15  35 
 
 
35 
MDZ 
 
 
DZP 
0.2 (IN) 
 
 
0.2 (IV) 
35                        35 
 
1 (0.9-1) 
p = 1 
Mean 2.5 min               Mean 2.6 min Data was not 
available 
Data was not 
available 
Total 2  0.2-15 56  
(61 episodes) 
58  
(61 episodes) 
MDZ 
 
DZP 
0.2 (IN) 
 
0.2-0.3 (IV) 
58                        59 
 
0.98 (0.91-1) 
p = 0.67 
2.5-3.1 min                       2.5-2.6 min 3                                2 
 
1.64 (0.3-8.8) 
p = 0.56 
1                         1 
 
1.1 (0.07-16.4) 
p = 0.95 
MDZ: Midazolam, DZP: Diazepam 
Data for whether additional dose(s) were administered was not reported 
* The seizure rate was measured within one hour. 
** Median. 
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Figure 3.4: The effectiveness of intranasal midazolam vs. intravenous diazepam 
1. Successful seizure control 
 
2. Additional AEDs 
 
3. Seizure recurrence 
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A.3. Buccal midazolam versus intravenous diazepam  
One study compared the efficacy of buccal midazolam against intravenous diazepam in 
children who attended the emergency room with convulsions, irrespective of duration. 
This randomised, single-blind, single-centre study in India was conducted by Talukdar 
et al. (2009) and involved 120 children aged less than 12 years of which 60 were treated 
with buccal midazolam [80]. Successful seizure remediation was defined as the ending 
of seizures within 5 minutes of the initial dose of study medications. When the seizures 
lasted longer than that, the local protocol was applied.  Children were excluded if they 
had the following seizure types: myoclonic, atonic, or absence. Selection of the study 
medication was performed with a random number table. Cardiorespiratory compromise 
was evaluated at 5 and 10 minutes after administration of the study medications. This 
study documented the treatment success and time to seizure control rather than seizure 
recurrence rate. 
The seizure stopped in 51 of 60 children (85%) who received buccal midazolam, and in 
56 of 60 children (90%) who received intravenous diazepam; the difference was not 
significant (RR: 0.9; 95% CI: 0.8 to 1.03; p = 0.15) (Table 3.7).  
Nor was there a significant difference in the time to seizure termination, with a mean of 
1.7 minutes for buccal midazolam and of 1.1 minutes for intravenous diazepam.  
Whether additional dose(s) were administered was not recorded. However, 9 children 
(15%) in the buccal midazolam group needed additional AEDs to terminate their 
seizures compared to 2 children (3%) in the intravenous diazepam group; the difference 
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was of borderline statistical significance (RR: 4.5; 95% CI: 1.01 to 19.96; p = 0.05) 
(Table 3.7). 
The recurrence rates were not reported. 
In conclusion, although the number of children whose seizure ended with buccal 
midazolam was lower than the intravenous diazepam group, the difference was not 
significant (Table 3.7 and appendix A). There was, however, a borderline statistical 
difference in the use of additional AEDs, favouring intravenous diazepam. 
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Table 3. 7: Buccal midazolam versus intravenous diazepam in one study 
Reference, 
country  
Study 
design  
Age 
(Y) 
No. of 
children  
AEDs Dose 
(mg/kg) 
Seizure control 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
MDZ            DZP 
Time to seizure control  
 
 
 
 
 
 
MDZ                                 DZP 
Additional AEDs  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
MDZ                          DZP 
Talukdar et 
al, 2009, 
India, [80] 
Singl blind 
RCT 
< 12 60 
 
 
60 
 
MDZ 
 
 
DZP 
0.2 BUC 
 
 
0.3 IV 
51                   56 
 
 
0.91 (0.8-1.03) 
p = 0.15 
Mean 1.7 min                    Mean 1.1  min 9                                      2 
 
 
4.5 (1.01-19.96) 
p = 0.05 
MDZ: Midazolam, DZP: Diazepam 
Data for whether additional dose(s) were administered and recurrence rate were not reported 
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A.4. Intramuscular midazolam versus intravenous diazepam 
One study in Brazil compared intramuscular (IM) midazolam and intravenous (IV) 
diazepam in 32 children who attended the emergency department with seizures, 
irrespective of type and duration [68]. Children were excluded if they had (IV) access 
prior to hospital admission, or a history of hepatic, renal or coagulopathic disorders. 
Children aged between 2 months and 14 years were randomly assigned (IM) midazolam 
or (IV) diazepam. Randomisation was performed by preparing blocks of 10 medications, 
5 of which were (IM) midazolam and 5 (IV) diazepam. The study was blinded to 
participants only. Treatment was considered to have failed if the seizures did not 
terminate within 5 minutes, or if patients required a second dose of study medication or 
additional AEDs. This study documented the treatment success and failure rates, but not 
the recurrence rate.  
The number of children who stopped seizing was the same in both groups (14 children, 
88%) (RR: 1; 95% CI: 0.77 to 1.3; p = 1).  
Seizure termination occurred within 4 minutes after treatment with intramuscular 
midazolam, and within 3 minutes after intravenous diazepam (Table 3.8). 
One child (6%) in each group required additional dose(s) of the study medication to 
control their seizures (RR: 1; 95% CI: 0.07 to 14.6; p=1).  
Two of 16 children (13%) with intramuscular midazolam required an additional AED to 
end their presenting seizure compared to one child (6%) who received intravenous 
diazepam (Table 4.8); the difference was not significant (RR: 2; 95% CI: 0.2 to 19.9; p 
= 0.5). The recurrence rate was not reported.   
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To summarise, this study showed equal effectiveness of intramuscular midazolam 
compared to intravenous diazepam (Table 3.8 and appendix A).  
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Table 3. 8: Intramuscular midazolam versus intravenous diazepam 
Reference, 
country  
Study 
design  
Age 
(Y) 
No. of 
children  
AEDs Dose 
(mg/kg) 
Seizure control 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
MDZ            DZP 
Time to seizure 
control  
 
 
 
 
 
MDZ                DZP 
Second dose(s)  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
MDZ                                 DZP 
Additional AEDs  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
MDZ                           DZP 
Portela et al, 
2014, 
Brazial [68] 
Singl 
blind 
RCT 
0.2-14 16 
 
 
16 
 
MDZ 
 
 
 
DZP 
0.2 IM 
(Max 15 mg) 
 
 
0.3 at 
5mg/min  IV 
(Max 10 mg) 
 
14                            14 
 
 
 
 
1 (0.77-1.3) 
p = 1 
4  min                     3  min 1                                                           1 
 
 
 
 
1 (0.07-14.64) 
p = 1 
9                                                   2 
 
 
 
 
2 (0.2-19.91) 
p = 0.55 
MDZ: Midazolam, DZP: Diazepam 
Data for recurrence rate was not reported 
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A.5. Summary of midazolam versus diazepam 
Four studies compared the effectiveness of buccal midazolam and rectal diazepam for 
treating acute tonic clonic seizure in children. Of these, three studies involving 605 
children (306 treated with buccal midazolam and 299 treated with rectal diazepam) 
showed that the effectiveness of buccal midazolam in seizure termination was superior 
to that of rectal diazepam (RR:1.89 & p = 0.001[78], RR: 1.22 & p = 0.02 [65] and RR: 
1.22 & p = 0.004 [79], respectively) (Table 4.5). These 3 studies provided the majority 
of the patients and were responsible for most of the significant differences in this 
systematic review. The fourth study showed no significant difference (p = 0.57)[73]. 
The overall pooled risk of ratio showed that the effectiveness of buccal midazolam in 
seizure termination was superior to that of rectal diazepam (RR: 1.29 & p < 0.04). 
In contrast, there were no significant differences in seizure termination between 
midazolam (intranasal, buccal or intramuscular) and diazepam (intravenous) (Table 3.6, 
3.7 and 3.8).  
Additional doses were only documented in one study [68] involving 16 children; there 
were no differences among the groups.  
The use of additional antiepileptic drugs (AEDs) to terminate seizures was documented 
in 6 studies [65, 66, 68, 73, 78, 80]. Two studies showed that the requirement of 
additional antiepileptic drugs was lower with buccal midazolam (median = 33%) than 
with rectal diazepam (median = 49%). 
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 The seizure recurrence rate was documented in 3 studies [65, 66, 78].  The 2 studies 
comparing buccal midazolam with rectal diazepam reported a lower likelihood of 
seizure recurrence with buccal midazolam 
In conclusion, buccal midazolam was more effective than rectal diazepam. Studies 
involving other routes of administration of the 2 drugs showed no difference between 
the 2 drugs. 
B. Lorazepam versus diazepam  
There were 3 studies that compared the effectiveness of lorazepam and diazepam, 
involving more than 700 children; one was open label [76], one a single-blinded study 
and  one was double-blinded [70, 75].  
B.1. Intravenous lorazepam vs. intravenous diazepam 
Two studies recruited a total of 334 children; one was open-label, while the second was 
double-blinded. 
Appleton et al. (1995) conducted a 12-month, single-centre, randomised, open-label 
study comparing lorazepam vs. diazepam in the UK. Children received one of the two 
drugs either intravenously or rectally [76]. The study recruited 102 children aged 
between one month and 16 years who attended the emergency department with an acute 
tonic-clonic convulsion. Sixteen children received the wrong medication and were 
therefore excluded. Sixty-one children received intravenous treatment (27 lorazepam 
and 34 diazepam). Randomisation was achieved by alternating the study medication 
daily. Treatment was considered effective if the presenting seizures terminated within 8 
minutes of the initial dose. If the seizures were still active after 8 minutes, a second dose 
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of the study medication was given by the same route. The local protocol was applied if 
the second dose was not effective.  
Efficacy and safety was assessed by the following measures: the time from drug 
administration to end of seizure, the incidence of respiratory depression, and the 
numbers of doses, children that required additional AEDs, and children with recurrent 
seizures in the first 24 hours. 
In the second study, Chamberlain et al. (2014) assessed the efficacy of intravenous 
lorazepam against intravenous diazepam in 273 children, aged from 3 months through 
17 years. One hundred and forty patients were given diazepam and 133 lorazepam [70]. 
This was a 4-year, double-blind, randomised clinical trial conducted in the USA at 11 
paediatric hospitals. Status epilepticus was defined as 3 or more seizures within the hour 
prior to emergency admission and still ongoing at the emergency room, or 2 or more 
seizures with loss of consciousness and still ongoing at the emergency room, or single 
current seizures lasting at least 5 minutes. Patients were excluded from the study if they 
were pregnant, attended with cardiovascular complications including hypotension or 
cardiac dysrhythmia, required surgical interventions or general anaesthesia, were 
contraindicated for benzodiazepines, had used benzodiazepines within 7 days prior to 
hospital admission, or had received prehospital AEDs.  
Randomisation was allocated within 3 age groups: 3 months - 2 years, 3 - 12 years, and 
13 - 17 years. A unique dispensing system distributed the medications in opaque 
syringes with cards attached that described how to use the treatment at the patient’s 
bedside.  
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If the seizures were controlled within 10 minutes of the initial dose, without recurrence 
for 30 minutes, the treatment was deemed successful. If the seizures remained active 
after 12 minutes from the benzodiazepine dose, phenytoin IV (15-20 mg/kg) or 
phenobarbital were used. If the seizure continued for more than 20 minutes from initial 
dose, the study became open-label, and AEDs were given according to the practitioner’s 
decision.  
The secondary outcomes included the number of children who required a second dose 
or additional AEDs in both treatment groups, and the number of children whose 
seizures were controlled for 1 and 4 hours after administration of the study medications. 
The primary safety outcome was respiratory depression within 10 minutes of the initial 
dose of the study medications; the secondary outcomes were incidences of aspiration 
pneumonia, sedation, or agitation, and time to recover consciousness.  
In the two studies, the seizure terminated in 116 of 160 children (73%) who received 
intravenous lorazepam and in 123 of 174 children (71%) who received intravenous 
diazepam. There was no difference between intravenous lorazepam and intravenous 
diazepam in achieving seizure termination (RR: 1.02, 95% CI: 0.89 to 1.17; p = 0.73) 
(Table 3.9). 
Seizure termination occurred 2 seconds to 2 minutes after treatment with lorazepam, 
and 2 seconds to 2.5 minutes after diazepam.  
Fifty-two of the 160 children (33%) given intravenous lorazepam required additional 
doses to terminate their seizure compared to 54 of the 174 children (31%) on 
intravenous diazepam. One study favoured lorazepam and the other diazepam. The 
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pooled risk ratio showed that the requirement of additional doses was similar (RR: 1.05; 
95% CI: 0.76 to 1.44; p = 0.77) (Table 3.9). 
Both studies showed that the requirement for additional antiepileptic drugs was slightly 
lower with intravenous lorazepam (22 children, 14%) than with intravenous diazepam 
(26 children, 15%); the difference was not significant (RR: 0.91, 95% CI: 0.54 to 1.55; 
p = 0.73) (Table 3.9).  
The seizure recurrence rates were lower for intravenous lorazepam (16 children, 10%) 
than for intravenous diazepam (23 children, 13%); however, the differences were not 
significant (RR: 0.79, 95% CI: 0.44 to 1.43; p = 0.44) (Table 3.9). 
To summarise, the two studies showed that intravenous lorazepam and intravenous 
diazepam were equally effective for treating acute tonic clonic seizures (Table 3.9 and 
Figure 3.5). 
A prospective comparative non-randomised study conducted by Wassmer et al. (2002) 
compared intravenous lorazepam and intravenous diazepam in the UK and also reported 
a similar result [84]. This study involved 48 children aged 5 months to 11 years with 
convulsive status epilepticus. A definition of convulsive status epilepticus was not given. 
Thirty-one children received intravenous lorazepam and 17 intravenous diazepam. The 
seizure was terminated in 20 children (65%) who received intravenous lorazepam and in 
11 (65%) receiving intravenous diazepam within 15 minutes.  
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Table 3. 9: Intravenous Lorazepam vs. Intravenous diazepam  
Reference, 
country  
Study 
design  
Age (Y) No. of 
children  
AEDs Dose 
(mg/kg) 
Seizure control 
(No. of children) 
 
RR (95% CI)  
P-value 
 
LZP            DZP 
Time to seizure control  
 
 
 
 
 
 
LZP                           DZP 
Additional dose(s)  
(No. of children) 
 
RR (95% CI)  
P-value 
 
LZP                DZP 
Additional 
AEDs (No. of 
children) 
 
RR (95% CI)  
P-value 
 
LZP            DZP 
Recurrence rate*  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
LZP                DZP 
Appleton et 
al., 1995, 
UK [76] 
Open 
label 
Quasi-
RCTs 
0.1-16  27 
 
34 
LZP 
 
DZP 
0.05-0.1  
(IV)  
 
0.3-0.4 (IV)  
 19                   22 
1.09 (0.77-1.54) 
p = 0.64 
20-60 sec.           20-60 sec.  8                        12 
0.84 (0.4-1.76) 
p = 0.64 
1                        5 
0.25 (0.03-2.03) 
p = 0.2 
6                         12 
0.63 (0.27-1.46) 
p = 0.28 
Chamberlain 
et al.., 2014, 
USA [70] 
Double 
blind 
RCT 
0.3- < 18 133 
 
140 
LZP 
 
 
DZP 
0.1 (IV), 
Max. 4 mg 
 
0.2 (IV),  
Max. 8 mg  
97                  101 
1.01 (0.87-1.17) 
p = 0.88 
2 min                    2.5 min 44                       42 
1.1 (0.78-1.56) 
p = 0.58 
21                    21 
1.05 (0.6-1.84) 
p = 0.86 
10                       11 
0.96 (0.42-2.18) 
p = 0.92 
Total 2 0.3- < 18 160 
 
174 
LZP 
 
 
DZP 
0.05-0.1 
(IV) 
Max 4 mg 
 
 
0.2-0.4 (IV) 
Max. 8 mg 
116                123 
1.02 (0.89-1.17) 
p = 0.73 
0.2 - 2 min     0.2 – 2.5 min 52                       54 
 
1.05 (0.76-1.44) 
p = 0.77 
22                    26 
0.91 (0.54 – 1.55) 
p = 0.73 
16                       23 
0.79 (0.44-1.43) 
p = 0.44 
LZP: Lorazepam, DZP: Diazepam   
* The first study documented the rate within 24 hours while the second study within one hr. 
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Figure 3. 5: The effectiveness of intravenous lorazepam vs. intravenous diazepam  
1. Successful seizure control 
 
2. Additional dose(s) 
 
3. Additional AEDs 
 
4. Seizure recurrence 
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B.2. Rectal lorazepam vs. rectal diazepam 
The  study by Appleton et al. (1995) described above in the previous section (section I) 
also compared rectal lorazepam and rectal diazepam in 25 children [76]. Six children 
received lorazepam and 19 received diazepam.  
Seizure termination occurred in all 6 children who received rectal lorazepam, compared 
to only 6 of 19 (32%) children who received rectal diazepam (Table 4.10). Lorazepam 
was more effective than diazepam in achieving seizure termination (RR: 2.8; 95% CI: 
1.5 to 5.5; p = 0.002) (Table 3.10) 
Thirteen children (68%) who received rectal diazepam required additional dose(s) (RR: 
0.1; 95% CI: 0.01-1.56, p = 0.1) and 12 children (63%) in the same group required 
different AEDs (RR: 0.2; 95% CI: 0.01-1.69, p = 0.1) to terminate their seizures (Table 
3.10).  
In the lorazepam group, none of the six children in the study experienced a further 
seizure within 24 hours of drug administration, compared to 7 children in the diazepam 
group; the difference was not significant (RR: 0.2; 95% CI: 0.01 to 2.9; p = 0.2) (Table 
3.10)  
In summary, in this small study rectal lorazepam was seen to be more effective than 
rectal diazepam for initial seizure control and was associated with no recurrent seizures 
within 24 hrs (Table 3.10 and appendix A). 
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Table 3. 10: Lorazepam (PR) versus diazepam (PR) in one study 
Reference, 
country  
Study 
design  
Age (Y) No. of 
children  
AEDs Dose (mg/kg) Seizure control 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
LZP                DZP 
Time to seizure control  
 
 
 
 
 
 
LZP                     DZP 
Additional dose(s)  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
LZP                     DZP 
Additional AEDs 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
LZP                 DZP 
Recurrence rate*  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
LZP                    DZP 
Appleton et 
al., 1995, UK 
[76] 
Open 
label 
Quasi-
RCT 
0.1-16  6 
 
19 
LZP 
 
DZP 
0.05-0.1  (PR)  
 
0.3-0.4 (PR)  
6                             6 
2.8 (1.5-5.5) 
p = 0.002 
20-60 seconds     20-60 seconds 0                             13 
0.1 (0.01-1.56) 
p = 0.1 
0                           12 
0.1 (0.01-1.69) 
p = 0.1 
0                               7 
0.2 (0.01-2.9) 
p = 0.2 
LZP: Lorazepam, DZP: Diazepam   
* Within 24 hours. 
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B.3. Sublingual lorazepam vs. rectal diazepam 
The efficacy of sublingual lorazepam was studied against rectal diazepam by Malu et al. 
(2013) [75]. This was an 18-month, randomised, controlled single-blind study of 
children admitted to the emergency room with seizures lasting more than 5 minutes. 
This study was conducted in sub-Saharan Africa at 9 different hospitals and involved 
436 children aged from 5 months to 10 years. Treatment was considered effective if the 
presenting seizures terminated within 10 minutes of the initial dose. If the seizures were 
still active after 10 minutes, a second dose of the study medication was given by the 
same route. If this was not effective, intravenous phenobarbital was administered (15 
mg/kg). 
Randomisation was allocated based on an alternate-days basis (i.e., on even days of the 
month, children received rectal diazepam, and on odd days they received sublingual 
lorazepam). At the emergency room, blood pressure and oxygen levels were monitored 
for the first 20 minutes of admission.  Monitoring was extended to 40 minutes for 
patients who needed a second dose, and supplemental oxygen was provided if oxygen 
saturation fell below 93%. Children were excluded if they had been administered AEDs 
prior to hospital attendance, had seizures lasting less than 5 minutes, or ejected the 
diazepam within 10 minutes. 
The seizure ended in 131 of 234 children (56%) who received sublingual lorazepam and 
in 160 of 202 children (79%) who received rectal diazepam (Table 4.11). This result 
significantly favoured rectal diazepam for seizure termination (RR: 0.71; 95% CI: 0.62 
to 0.81; p < 0.00001) (Table 3.11).  
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Seizure termination occurred within 9 minutes after treatment with sublingual 
lorazepam, and within 6 minutes after rectal diazepam. 
Sixty-three of the 234 children (27%) treated with sublingual lorazepam required 
additional dose(s) to terminate their seizures compared to 24 of the 202 children (12%) 
on rectal diazepam; the differences was significant (RR: 2.3, 95% CI: 1.5 to 3.5; p = 
0.0002) (Table 3.11) 
Data related to additional AEDs was not available. 
Eighty-five of the 234 children (36%) treated with sublingual lorazepam experienced a 
further seizure after drug administration compared to 80 of the 202 children (40%) 
given rectal diazepam; the difference was not significant (RR: 0.92, 95% CI: 0.72 to 
1.17; p = 0.48) (Table 3.11).  
To conclude, sublingual lorazepam was inferior to rectal diazepam for the treatment of 
acute seizures in children. It was less effective and more likely to require an additional 
dose(s) (Table 3.11 and appendix A). 
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Table 3. 11: Lorazepam sublingual versus rectal diazepam in one study 
Reference, 
country  
Study 
design  
Age (Y) No. of 
children  
AEDs Dose (mg/kg) Seizure control 
(No. of children) 
 
 
RR (95% CI)  
P-value 
 
 
LZP                            DZP 
Time to seizure control  
 
 
 
 
 
 
 
LZP                          DZP 
Additional dose(s)  
(No. of children) 
 
 
RR (95% CI)  
P-value 
 
 
LZP                     DZP 
Recurrence rate*  
(No. of children) 
 
 
RR (95% CI)  
P-value 
 
 
LZP                    DZP 
Malu et al., 
2013, sub-
Saharan 
Africa [75] 
single-
blind 
RCT 
0.5-10  234 
 
202 
LZP 
 
DZP 
0.1  (sublingual)  
 
0.3-0.4 (PR) ≤60 seconds 
131                              160 
0.71 (0.62-0.81) 
p < 0.00001 
9 min                         6 min  63                           24 
2.27  (1.5-3.5) 
p = 0.0002 
85                            80 
0.92 (0.72-1.17) 
p = 0.48 
LZP: Lorazepam, DZP: Diazepam   
Data for whether additional AEDs were administered was not reported 
* Within 24 hours. 
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B.4. Summary of lorazepam vs. diazepam 
The results suggest that IV lorazepam and IV diazepam are equally effective in 
terminating seizures (RR: 1.02 & p = 0.73) and there were no differences between the 
groups in term of additional doses (RR: 1.05 & p = 0.77), additional AEDs (RR: 0.91 & 
p = 0.73) and seizure recurrence (RR: 0.79 & p =0.44) (Table 3.9). 
With regard the rectal route, there was one study involving a small number of children 
which makes it difficult to conclude anything in relation to effectiveness [76]. 
Sublingual lorazepam appears to be inferior to rectal diazepam for the treatment of 
acute seizures in children (RR: 0.71 & p < 0.00001) and this may due to its poor 
absorption. A pharmacokinetic study conducted by Anderson et.al (2012) showed that 
lorazepam was slowly absorbed following buccal administration [85]. Sublingual 
absorption is likely to be similar to buccal absorption. Peak absorption following buccal 
administration was at 180 minutes, suggesting that this may not be the best route for 
treating acute seizures [85]. 
In summary, intravenous lorazepam is the best route of administration for this drug. 
Intravenous lorazepam and diazepam appear to be equally effective 
 
 
 
 
 
 
4 The Effectiveness of AEDs for convulsive status epilepticus (CSE) 
 
71 
 
C.  Lorazepam versus paraldehyde 
Shafique et al. (2006) compared intranasal lorazepam (100 µg/kg) and intramuscular 
paraldehyde (0.2 ml/kg) in a 12-month, single-centre, randomised, open-label study 
conducted in sub-Saharan Africa [72]. It was carried out in 160 children aged 2 months 
to 12 years who attended the paediatric emergency department with generalized 
convulsions continuing for at least 5 minutes.  
Children were excluded if they received antiepileptic drugs within 1 hour before 
attending, had seizures due to hypoglycaemia which were stopped with its correction, 
had signs of hepatic or hypertensive encephalopathy, or suffered organophosphate 
poisoning. Randomisation was assigned by computer, and treatment was allocated in 
unmarked sealed envelopes. 
The primary outcome was whether the seizures stopped within 10 minutes of treatment. 
The secondary outcomes were time to seizure cessation, incidence of hypotension or 
hypoxia, and the seizure recurrence rate within 24 hours. The local protocol was applied 
for children whose seizures lasted more than 10 minutes.  
Intranasal lorazepam was more effective than intramuscular paraldehyde in terminating 
seizures (60 children (75%) terminated their seizure vs. 49 children (61%)).  However, 
this difference was not statistically significant (RR: 1.22; 95% CI: 0.9 to 1.52; p = 0.07) 
(Table 3.12 and appendix A).  
There was no difference between medications in the time to achieve seizure termination, 
7.5 minutes (median) for intranasal lorazepam and 8 minutes (median) for intramuscular 
paraldehyde. 
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Significantly fewer children receiving intranasal lorazepam (8 children, 10%) required 
an additional dose(s) and different antiepileptic drugs to terminate their seizures than 
with intramuscular paraldehyde (21 children, 26%) (RR: 0.38; 95% CI: 0.18 to 0.88; p = 
0.01) (Table 3.12 and appendix A). 
The seizure recurrence rate was 10% (8 children) for intranasal lorazepam compared to 
14% (11 children) for intramuscular paraldehyde; the difference was not significant (RR: 
0.73; 95% CI: 0.31 to 1.71; p = 0.47) (Table 3.12 and appendix A). 
In summary, children receiving intranasal lorazepam as opposed to intramuscular 
paraldehyde were significantly less likely to require additional dose(s) or an alternative 
antiepileptic drug. It appeared to be more effective, but this difference was not 
statistically significant 
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Table 3. 12: Lorazepam (intranasal) vs. paraldehyde (intramuscular) in one study 
Reference, 
country  
Study 
design  
Age (Y) No. of 
children  
AEDs Dose  Seizure control 
 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
LZP              Paraldehyde 
Time to seizure control  
 
 
 
 
 
 
 
LZP                               Paraldehyde 
Additional dose(s) 
and AEDs* 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
LZP       Paraldehyde 
Recurrence rate** 
 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
LZP           Paraldehyde 
Shafique et 
al., 2006, 
sub-Saharan 
Africa [72] 
Open 
label 
RCT 
0.2-12  80 
 
80 
LZP 
 
Paraldehyde 
100 μg/kg  (IN)  
 
0.2 ml/kg (IM)  
60                                   49 
1.22 (0.9-1.52) 
P = 0.07 
Median 7.5 min              Median 8 min  (8)                       (21) 
0.38  (0.18-0.88) 
p = 0.01 
8                                  11 
0.73 (0.31-1.17) 
p = 0.47 
LZP: Lorazepam 
* The data for the requirement of additional dose(s) and AEDs was combined in this study. 
** Within 24 hours. 
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D. Intravenous lorazepam vs. intravenous diazepam plus phenytoin 
A 2010 study compared intravenous lorazepam with an intravenous combination of 
diazepam and phenytoin in a tertiary hospital in India [81]. The study was randomised 
and open-label. Phenytoin was given 15 to 30 minutes after diazepam administration, 
even if seizures had not recurred. The study included178 children aged between 1 and 
12 years with convulsive status epilepticus lasting for at least 5 minutes. If IV access 
could not be obtained, the same dose of lorazepam and diazepam was given rectally.  
Children were excluded if they received antiepileptic drugs within the past 4 weeks or 
had headache, injury, jaundice, diarrhoea, renal failure or a history of poisoning.  
Randomisation was assigned by a computer, and treatment was allocated in sealed 
envelopes.  
If the seizures were controlled within 10 minutes of the initial seizure, without 
recurrence for 18 hours, the treatment was deemed successful. 
The primary outcome was seizure cessation within 10 minutes of the first intervention, 
without recurrence of seizures during the next 18 hours. If the seizures did not stop 
immediately after the initial dose, a second dose of the same medication was used 
during the first 10 minutes from the initial seizure. If the seizure was still active after the 
second dose (after 10 minutes from the initial seizures), the following medications were 
used: phenytoin (18 mg/kg, IV), phenobarbital (20 mg/kg, IV) and midazolam (1–5 
µg/kg/min, IV).  
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The secondary outcomes included time to stop seizure after the first dose, number of 
doses required to stop the initial seizures, number of seizures during 18 hours after the 
initial dose, incidence of respiratory depression, number of children who crossed over to 
another treatment regimen and number of cases transferred to the ICU. The study period 
was not documented. 
The authors described both medicines to be effective in all patients (RR: 1; 95% CI: 
0.98 to 1.02; p = 1), However, their definition of being effective included the use of a 
second dose of the anticonvulsant. Six (7%) of 90 children on intravenous lorazepam 
required an additional dose to terminate their initial seizure, compared with 14 of 88 
children (16%) on intravenous diazepam and phenytoin (i.e. the effectiveness of 
lorazepam was 93% compared to 84% for diazepam with phenytoin).  The difference 
was not statistically significant (RR: 1.1; 95% CI: 0.17 to 1.04; p = 0.06) (Table 3.13 
and appendix A). All of the doses were received during the first 10 minutes of the 
emergency admission.  
No children in either group required an additional antiepileptic drug or had a further 
seizure within 18 hrs after drug administration and this result was due to the longer 
action of duration of lorazepam and the use of the long-acting AED (phenytoin) along 
with diazepam (Table 3.13).  Intravenous diazepam has a short duration of action, and 
seizure recurrence may occur within 2 hours after diazepam administration [86]. 
Moreover, the recommended concentration of diazepam to terminate a seizure is 200 
μg/L, but this concentration decreases in less than 50 minutes after the dose is given, 
which explains the rapid recurrence of seizure [87]. Therefore, seizures may recur with 
4 The Effectiveness of AEDs for convulsive status epilepticus (CSE) 
 
76 
 
diazepam if patients are not given a loading dose of long-acting AEDs, such as 
phenytoin [81]. By contrast, intravenous lorazepam has a long action of duration, which 
helps avoid seizure recurrence within 18 hours after seizure termination [81]. 
In summary, intravenous lorazepam appeared to be more effective than the intravenous 
combination of diazepam and phenytoin in the treatment of acute seizures. The 
difference was of borderline statistical significant (RR: 1.1; 95% CI: 1 to 1.23; p = 0.05). 
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Table 3. 13: Intravenous lorazepam vs. intravenous diazepam plus phenytoin in one study 
Reference, 
country  
Study 
design  
Age 
(Y) 
No. of 
children  
AEDs Dose (mg/kg) Seizure control 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
 
LZP                        DZP+PHT 
Time to seizure control  
 
 
 
 
 
 
 
LZP       DZP+PHT 
Additional dose(s)* 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
 
LZP                           DZP+PHT  
Sreenath 
et al., 
2010, 
India [81] 
Open 
label 
RCT 
1–12  90 
 
88 
LZP 
 
DZP+PHT 
0.1 (IV)  
 
0.2 + 18/15–30 min  (IV)  
  
84                                          74 
1.1 (1 –1.23) 
P = 0.05 
20 sec      20 sec 6                                               14  
 0.42 (0.17–1.04) 
P = 0.06         
LZP: Lorazepam, DZP: Diazepam, PHT: Phenytoin 
* All additional doses are given within the first 10 minutes of the initial seizure 
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E. Intravenous lorazepam vs. intranasal lorazepam 
Two studies recruited a total of 650 children aged between 2 months and 14 years; one 
was conducted in India [69] and the other in Malawi [71]. 
Arya et al. (2011) conducted the randomised, open-label, single-centre study in India 
[69]. The researchers recruited 141 children aged between 6 and 14 years who attended 
the emergency department with an acute tonic-clonic convulsion, over a 7 month period, 
and compared intravenous to intranasal lorazepam administration. The primary outcome 
was clinical termination of the seizure activity within 10 minutes of drug administration. 
If the seizure continued or recurred after 10 minutes from the initial dose, phenytoin 
was given at 20 mg/kg over 20 minutes. Secondary outcomes were persistent 
termination of seizures for 1 hour after drug administration, time for seizure control, 
incidence of hypotension within 1 hour of drug administration, and incidence of 
respiratory depression needing ventilation. Children were excluded if they were 
hypersensitive to benzodiazepine, had received intravenous AEDs within 1 hour prior to 
being admitted to the emergency room, or appeared to have cerebrospinal fluid 
rhinorrhoea or upper respiratory tract infection. Advance randomisation was performed 
using blocks of variable lengths and storing the medication in opaque sealed envelopes.  
Four years later, Lissauer et al. (2015) conducted a randomised, open-label study at a 
single centre in Malawi comparing intravenous to intranasal lorazepam. The study 
period was not documented. Five hundred and nine children aged from 2 months to 14 
years who attended the emergency department with acute generalised seizures lasting at 
least for 5 minutes were included. Lorazepam was given intravenously to 264 children 
4 The Effectiveness of AEDs for convulsive status epilepticus (CSE) 
 
79 
 
and intranasally to 245. Randomisation was computer-generated via a number table, in 
blocks of 10, and stratified depending on whether IV access was available, already 
established or could not be obtained. The primary endpoint was control of seizures 
within 10 minutes of the initial dose. The secondary outcomes included the time to stop 
seizure after the first dose, number of doses, additional AEDs, recurrence within 24 
hours, length of seizure, side effects and the patients’ health status at discharge. 
Treatment was considered effective if the presenting seizure terminated within 10 
minutes of the initial dose. If the seizures were still active after 10 minutes, a second 
dose was given by the same route. If the seizure lasted for 20 minutes or more, the 
following medications were used: intramuscular paraldehyde (0.2ml/kg) followed by 
intravenous phenobarbital (18 mg/kg), then intravenous phenytoin (18 mg/kg/10minutes) 
as necessary, according to local guidelines. 
The seizure ended in 274 of 334 children (82%) who received intravenous lorazepam 
and in 198 of 316 children (63%) who received intranasal lorazepam (Table 3.14). 
There was no difference statistically (RR: 1.19; 95% CI: 0.78 to 1.81; p = 0.42). Seizure 
termination was statistically higher with intravenous lorazepam in one study (RR: 1.46 
& p < 0.00001) [71]. In the other study, however, there was no difference between the 2 
routes (RR: 0.96 & p = 0.64)[69]. Seizure termination occurred 3 to 5 minutes after 
treatment with intravenous lorazepam, and 3 to 10 minutes after intranasal lorazepam.  
One of the studies involving 509 children recorded whether an additional dose(s) and 
additional AEDs were needed [71]. Forty-six of the 264 children (17%) receiving 
intravenous lorazepam required additional dose(s) compared to 99 of the 245 children 
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(40%) who received intranasal lorazepam (Table 4.16); the difference was statistically 
significant (RR: 0.4; 95% CI: 0.32 to 0.58; p < 0.00001) (Table 3.14).  
The intravenous route had a lower likelihood of requiring a different AED to terminate 
the seizure (23 children, 9%) than the intranasal route (56 children, 23%) (RR: 0.38; 
95% CI: 0.24 to 0.6; p < 0.0001) (Table 3.14). 
Eighty-eight of the 334 children (26%) on intravenous lorazepam experienced a further 
seizure after drug administration compared to 106 of the 316 children (34%) on 
intranasal lorazepam; the difference was not significant (RR: 0.7; 95% CI: 0.61 to 1.12; 
p = 0.23) (Table 3.14). 
In conclusion, intravenous lorazepam appeared to be more effective than the intranasal 
lorazepam in the treatment of acute seizures with a lower recurrence rate of seizures. 
These differences however did not reach statistical significance. There was however a 
statistically lower risk of needing treatment with additional dose(s) and additional AEDs, 
favouring intravenous lorazepam (Table 3.14 and Figure 3.6). 
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Table 3. 14: Lorazepam (IV) versus lorazepam (IN)  
Reference, 
country  
Study 
design  
Age (Y) No. of 
children 
AED Dose (mg/kg) Seizure control 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
IV                      IN 
Time to seizure control  
(median) 
 
 
 
 
 
IV                               IN 
Additional dose(s)  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
IV                        IN 
Additional AEDs  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
IV                        IN 
Recurrence* 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
IV                          IN 
Arya et al., 
2011, India 
[69] 
Open 
label  
6-14  70 
 
 
 
71 
LZP 
 
 
LZP 
0.1 (IV), 4 mg max. 
 
 
 
0.1/30-60 sec (IN) 
 
56                       59 
 
0.96 (0.82-1.13) 
p = 0.64 
3 min                           3 min  NA                      NA NA                      NA 41                           44 
 
0.95 (0.72-1.24) 
p = 0.68 
Lissauer et 
al. ,2015, 
Malawi [71] 
Open 
label 
0.2-14 264 
 
245 
LZP 
 
LZP 
0.1 (IV) 
 
 
0.1(IN) 
 
218                    139 
1.46 (1.29-1.65) 
p < 0.00001 
5 min                         10 min 46                            99 
0.4 (0.32-1.58) 
p < 0.00001 
23                          56 
0.38 (0.24-0.6) 
p < 0.0001 
47                            62 
0.7 (0.5-0.99) 
p = 0.04 
Total 2 0.2-14 334 
316 
LZP 
LZP 
0.1 (IV), 4 mg max. 
 
0.1/30-60 sec (IN) 
 
274                    198 
1.19 (0.78-1.81) 
p = 0.42 
3-5 min                   3-10 min 46                            99 
0.4 (0.32-1.58) 
p < 0.00001 
23                          56 
0.38 (0.24-0.6) 
p < 0.0001 
88                          106 
0.83 (0.61 – 1.12) 
p = 0.23 
IV: Intravenous, IN: Intranasal 
*  The first study documented the rate within 1 hour while the second study within 24 hours.
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Figure 3. 6: The effectiveness of lorazepam at different route of the administration (IV vs IN) 
1. Successful seizure control 
 
2. Additional dose(s) 
 
3. Additional AEDs 
 
4. Seizure recurrence 
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F. Intravenous lorazepam vs. buccal lorazepam 
The Lissauer et al. (2015) study described in the previous section (intravenous vs. 
intranasal lorazepam) also compared intravenous vs. buccal lorazepam[71].  
Seizures ended in 218 of 264 children (83%) who received intravenous lorazepam, and 
in 115 of 252 children (46%) after buccal lorazepam (Table 3.15 and appendix A). The 
results favoured intravenous lorazepam over the buccal route for seizure termination 
(RR: 1.81; 95% CI: 1.56 to 2.09; p < 0.00001) (Table 3.15 and appendix A).  
Forty-six children (17%) receiving intravenous lorazepam required additional dose(s) 
compared to 130 children (51.5%) who received buccal lorazepam. The result revealed 
that children treated with intravenous lorazepam were significantly less likely to need a 
second dose (RR: 0.34; 95% CI: 0.25-0.45; p < 0.00001) (Table 3.15 and appendix A).  
The intravenous route also had a significantly lower likelihood of requiring a different 
AED to terminate the seizure (23 children, 9%) than the buccal route (80 children, 32%) 
with significant differences between both routes, favouring intravenous (RR: 0.27; 95% 
CI: 0.18-0.42; p < 0.00001) (Table 3.15 and appendix A). 
The seizure recurrence rate within 24 hours was similar between the administration 
routes, 47 children for intravenous and 48 for buccal and the risk ratio did not prove to 
be significant (RR: 0.7; 95% CI: 0.61 to 1.12; p = 0.23) (Table 3.15 and appendix A). 
In summary, intravenous lorazepam was found to be superior to buccal lorazepam for 
the treatment of acute seizures in children. It was more effective and less likely to 
require additional dose(s) or further AEDs to terminate seizures (Table 4.17 and 
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appendix A). This suggests that buccal lorazepam is poorly absorbed. As previously 
mentioned, a pharmacokinetic study conducted by Anderson et.al (2012) has shown that 
lorazepam was slowly absorbed following buccal administration [85]. Peak absorption 
following buccal administration was at 180 minutes, suggesting that this may not be the 
best route for treating acute seizures [85]. The findings in relation to buccal lorazepam 
are similar to those described earlier for sublingual lorazepam. (See section B part B.3 
& B.4). 
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Table 3. 15: Lorazepam (IV) versus lorazepam (buccal)  
Reference, 
country  
Study 
design  
Age (Y) No. of 
children 
AED Dose (mg/kg) Seizure control 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
IV                   BUC 
Time to seizure control  
(median) 
 
 
 
 
 
IV                               BUC 
Additional dose(s)  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
IV                       BUC 
Additional AEDs  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
IV                      BUC 
Recurrence* 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
IV                       BUC 
Lissauer et 
al. ,2015, 
Malawi [71] 
Open 
label 
0.2-14 264 
 
252 
LZP 
 
LZP 
0.1 (IV) 
 
 
0.1(BUC) 
 
218                   115 
1.81 (1.56-2.09) 
p < 0.00001 
5 min                         12 min 46                         130 
0.34 (0.25-0.45) 
p < 0.00001 
23                           80 
0.27 (0.18-0.42) 
p < 0.00001 
47                           48 
0.93 (0.65-1.34) 
p = 0.72 
IV: intravenous; BUC: buccal 
* Within 24 hours 
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G. Intravenous valproate vs. intravenous phenytoin 
The efficacy of intravenous valproate and intravenous phenytoin were compared in a 
15-month, single-centre, mixed-population, randomised study conducted by Agarwal et 
al. (2007) in India [77]. A group of 100 adults and children who had benzodiazepine-
resistant status epilepticus was divided into 2 sets of 50 patients. Group A, with a subset 
of 22 patients aged below 18 years, were given intravenous valproate (20mg/kg at 
40mg/min). Group B, with a subset of 16 patients aged below 18 years, were given 
intravenous phenytoin (20mg/kg at maximum 50mg/min). Treatment was considered 
successful if the convulsion terminated within 20 minutes after starting the infusion and 
if there was no recurrence over the next 12 hours. If the seizures were still active after 
20 minutes, or recurred after 12 hours of treatment, the crossover treatment was applied. 
Patients were excluded if they were aged under 2 years or had hepatic encephalopathy, 
myoclonic status epilepticus, or a history of benzodiazepine or barbiturate 
contraindication.  
The only data for the paediatric population in this study was seizure termination. The 
seizure stopped in 20 of 22 children (91%) who received intravenous valproate, and in 
14 of 16 children (88%) who received intravenous phenytoin; the difference was not 
significant (RR: 1.04; 95% CI: 0.8 to 1.3; p = 0.74) (Table 3.16 and appendix A). 
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Table 3. 16: Valproate (IV) versus phenytoin (IV) in one study 
Reference, 
country  
Study 
design  
Age (Y) No. of 
children 
AED Dose (mg/kg) Seizure control 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
VAP                PHT 
Time to seizure control  
(median) 
 
 
 
 
 
VAP                          PHT 
Additional dose(s)  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
IV                          PHT 
Additional AEDs  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
IV                       PHT 
Recurrence 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
IV                       PHT 
Agarwal et 
al. ,2007, 
India [77] 
Open 
label 
RCT 
0-18 22 
 
16 
VAP 
 
PHT 
20 (IV) 
 
 
20 (IV) 
 
20                      14 
1.04 (0.8-1.3) 
p = 0.74 
Data was not available  Data was not available Data was not 
available 
Data was not 
available 
VAP: Valproate, PHT: Phenytoin 
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H. Valproate versus phenobarbital 
An Iranian study compared intravenous valproate to intravenous phenobarbital in the 
treatment of acute prolonged seizures at 2 centres in 2012 [67]. This randomised, 
double-blind study took place over 2 years and involved 60 children aged between 3 
and 16 years old who attended the emergency room with seizures lasting more than 5 
minutes, which had not been controlled by intravenous diazepam (0.2mg/kg). 
The children were excluded if they had a history of an adverse reaction to sodium 
valproate, or coagulopathy, hepatic, or cardiovascular problems, or were on lamotrigine 
at more than 200 mg/day. Advance randomisation was allocated by a random number of 
tables in a quaternary block and children received either intravenous valproate (20 
mg/kg at maximum 5-6 mg/min) as a rapid loading dose over 5-10 minutes or 
intravenous phenobarbital (20 mg/kg at maximum 60-100 mg/min). Treatment was 
considered successful if the seizure stopped within 20 minutes of the start of infusion of 
the initial study medication, without respiratory depression, hypotension, or recurrent 
seizure within 24 hour.  
The seizure stopped in 27 of 30 children (90%) who received intravenous valproate, and 
in 23 of 30 children (77%) who received intravenous phenobarbital; the difference was 
not significant (RR: 1.17; 95% CI: 0.93 to 1.48; p = 0.17) (Table 3.17 and appendix A).  
There was no difference in the time to end seizures which was less than 20 minutes for 
each medication.  
Whether additional dose(s) or antiepileptic drugs were required to terminate seizures 
was not documented. 
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Four of the 30 children (13%) in the intravenous valproate group experienced a further 
seizure within 24 hours, compared to 12 of the 30 children (40%) who received 
intravenous phenobarbital; the difference was statistically significant (RR: 0.33; 95% CI: 
0.12 to 0.92; p = 0.03) (Table 3.17).  
This study showed that children receiving intravenous valproate were significantly less 
likely to have seizure recurrence within 24 hrs compared to those receiving intravenous 
phenobarbital. It appeared to be more effective, but this difference was not statistically 
significant (Table 3.17 and appendix A). 
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Table 3. 17: Valproate (IV) versus phenobarbital (IV) in one study 
Reference, 
country  
Study 
design  
Age (Y) No. of 
children 
AED Dose (mg/kg) Seizure control 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
VAP                   PB 
Time to seizure control  
(median) 
 
 
 
 
 
VAP                             PB 
Additional dose(s)  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
VAP                         PB 
Additional AEDs  
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
VAP                        PB 
Recurrence* 
(No. of children) 
 
RR (95% CI)  
P-value 
 
 
VAP                   PB 
Malamiri et 
al. ,2012, 
India [67] 
Double-
blind 
RCT 
3-16 30 
 
30 
VAP 
 
PB 
20 at 5 - 6mg/min (IV) 
 
 
20 at 60 - 100 mg/min (IV) 
 
27                       23 
1.17 (0.93 -1.48) 
p = 0.17 
< 20 min              <20 min  Data was not available Data was not available 4                         12 
0.33 (0.12 - 0.92) 
p = 0.03 
VAP: Valproate, PB: Phenobarbital 
* Within 24 hours. 
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3.3.2.2 Additional studies  
Lewena and Young (2006) conducted a retrospective study in Australia, which involved 
37 children ages 2 months to 7 years old who presented at an emergency department 
with convulsive status epilepticus lasting at least 10 minutes [83]. The primary aim of 
the study was to determine the effectiveness of second-line treatment. There was no 
clear definition of a successful treatment rate.  
All the children received benzodiazepines as first-line treatment; 30 intravenous 
diazepam, (0.1 - 0.2 mg/kg). The seizure ended in 5 of 37 children (14%). Thirty-two 
children (86%) required further treatment; as a second-line treatment; 11 phenytoin, 10 
phenobarbital, and 7 both agents (the doses were not documented). The seizure 
terminated in only 6 of the 28 children (21%) who received the second-line treatment. 
The low response rate suggests that either the doses given were inadequate or possibly 
the notes were reviewed incorrectly. However, as the doses of the second line 
treatments and other benzodiazepines were not stated, and it was a retrospective study, 
it has been excluded from further analysis. 
Garr et al. (1999) conducted a retrospective study to compare the effectiveness of rectal 
and intravenous diazepam (0.4 mg/kg, max 10 mg) in children aged 1 month to 15 years 
with tonic-clonic convulsions in the UK [82]. No specific definition of tonic-clonic 
convulsions was given in this study. The primary outcome was to identify at what stage 
of treatment protocol the seizure was controlled. The secondary outcome was to 
determine the safety of the medication used. 
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Of the 81 children, 48 received rectal diazepam, while 33 received intravenous 
diazepam. The seizure was terminated in 41 out of 48 children (85%) in the rectal 
diazepam group and 28 out of 33 children (85%) in the intravenous diazepam group 
after the first dose. Two children in each group required a second dose. Ten children 
were treated with paraldehyde and phenytoin (the doses were not documented) as 
additional AEDs to control their seizure, resulting in termination of the seizure in 5 
children. The result of this study suggested that rectal diazepam was effective as 
intravenous diazepam. 
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3.4  Discussion 
This systematic review has shown that buccal midazolam was more effective in 
terminating seizures in children suffering from acute tonic-clonic seizures  than rectal 
diazepam, with a success rate ranging from 53 to 100% (RR: 1.23; 95% CI: 1 to 1.5;  p 
< 0.04).  The important aim in treating acute tonic clonic convulsions in children is to 
control the seizures as quickly as possible, thereby preventing the seizures from 
developing into the refractory or super refractory status epilepticus phase, which may 
lead to neuronal damage [30, 31]. The children receiving rectal diazepam need to be laid 
in the appropriate position, which may cause a delay in drug administration; this does 
not happen with the administration of buccal midazolam [21]. The means of 
administering buccal midazolam is easier and is more socially acceptable in comparison 
to the rectal method [27]. The results of this systematic review also showed that seizure 
recurrence is lower in children receiving buccal midazolam than in those who receive 
rectal diazepam. This could be because buccal midazolam acts over a long duration. The 
half-life of midazolam ranges from two to three hours for a healthy child and more than 
five hours for ill children, while the half-life of diazepam is one hour [32, 33]. 
Therefore, buccal midazolam should be the first choice for treating acute tonic clonic 
convulsion in children when intravenous access is difficult or is yet to be obtained [21].  
When evaluating intravenous AEDs, our results showed that intravenous lorazepam and 
intravenous diazepam are equally effective in treating acute tonic-clonic seizures in 
children. The study by Appleton had suggested that lorazepam may be more effective, 
showing the need for less additional AEDs and a lower recurrence rate. However, the 
number of patients in this study were small [76]. 
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 Pharmacologically, one would expect a longer duration of action with lorazepam. More 
studies are needed to determine whether IV lorazepam is more effective than IV 
diazepam. 
Sublingual/buccal lorazepam, however, was inferior to rectal diazepam and intravenous 
lorazepam for the treatment of acute seizure in children. It was less effective and more 
likely to require additional dose(s) or further AEDs to terminate the seizures. This 
suggests that sublingual/buccal lorazepam is poorly absorbed. A pharmacokinetic study 
conducted by Anderson et al. (2012) showed that lorazepam was slowly absorbed 
following buccal administration [27]. Sublingual absorption is likely to be similar to 
buccal absorption. Peak absorption following buccal administration was at 180 minutes, 
suggesting that this may not be the best route for treating acute seizures [27]. 
Only one study was identified in this review which evaluated the effectiveness of 
intramuscular paraldehyde. It was as effective as intranasal lorazepam for treating acute 
tonic-clonic seizures in children but those children treated with intramuscular 
paraldehyde were more likely to require additional dose(s) or alternative AEDs. This 
could be because of the slower absorption of paraldehyde when given by the 
intramuscular route which delays the circulation of paraldehyde to the brain [14]. 
Fewer randomised controlled trials evaluating the second-line treatments (VAP, PB and 
PHT) were identified in this systematic review. Our results showed that intravenous 
valproate appeared to be more effective than intravenous phenytoin and phenobarbital; 
however, this was not statistically significant. Several studies have recommended 
levetiracetam instead of sodium valproate or phenytoin as a second-line treatment 
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following the failure of benzodiazepines [6, 34-38]. However, to date, no randomised 
control studies have been published comparing the effectiveness of intravenous 
levetiracetam with other second-line agents for treating convulsive status epilepticus in 
children.  More RCTs should be conducted to evaluate the effectiveness of these agents 
in treating children’s convulsive status epilepticus. 
3.5  Limitations 
The studies included in this review have a number of limitations. The majority of 
studies were open label, which may affect the quality of a study. In general, the number 
of studies included was small, and the definitions of the effectiveness and the 
measurement of seizure recurrence varied amongst them. Therefore, the interpretation 
of these outcomes is subjective (depends on the time of follow-up). Fewer studies were 
identified in this systematic review for second-line treatment; thus, the results of these 
studies should be interpreted with caution. 
3.6  Conclusions 
Buccal midazolam was more effective in seizure termination in children suffering from 
acute tonic-clonic seizures than rectal diazepam, and it was associated with a lower rate 
of seizure recurrence. This suggests that the buccal route may the best route of 
administration when children are initially admitted to the emergency department. 
However, the intravenous route is the better route of administration for lorazepam 
compared to the buccal, sublingual, or intranasal routes. More randomised control trials 
are required to compare second-line treatments. 
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CHAPTER 4: SYSTEMATIC REVIEW TWO  
4.1 Introduction 
The mortality associated with status epilepticus ranges from approximately 3% to 40%, 
and the prolonged convulsions can be associated with hypoxia, hypotension, respiratory 
depression and increased intracranial pressure [1, 88]. Because the mortality and 
morbidity that results from acute tonic seizures are correlated with the duration of the 
seizures, the first priority for treatment is to control the seizure as quickly as possible 
[89]. Therefore, the best treatment for acute tonic clonic seizure should be characterised 
by safe and rapid effectiveness with minimal recurrence. Not all treatments that are 
currently used to manage acute tonic clonic seizure meet all these criteria [76].  
Benzodiazepines are commonly used as the first line treatment for acute tonic clonic 
seizures. Lorazepam is the best choice as it has good effectiveness and a low incidence 
of respiratory depression [76, 90]. In contrast, diazepam has a higher risk of respiratory 
depression [65, 73, 76]. 
When two doses of benzodiazepine fail to control seizures, phenytoin or phenobarbital 
are the recommended second line treatments [38]. The Status Epilepticus Working Party 
preferred phenytoin over phenobarbital, as it caused less respiratory depression [91]. 
Several studies have recommended levetiracetam instead of phenytoin or phenobarbital 
or sodium valproate as a second-line treatment following the failure of benzodiazepines 
[51, 53, 92-94]. Recent cohort studies of intravenous levetiracetam in children have 
reported no serious AEs such as respiratory depression [51, 95, 96]. However, to date, 
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no randomised control studies comparing the safety of intravenous levetiracetam with 
other second-line agents for treating convulsive status epilepticus in children have been 
published. 
The primary aim for this review was to evaluate the safety of the following antiepileptic 
drugs, irrespective of the administration routes, for the treatment of acute tonic-clonic 
seizures including convulsive status epilepticus in children: benzodiazepines, 
paraldehyde, phenobarbital, phenytoin, sodium valproate and levetiracetam. 
4.2  Methods 
The methods used for this review are the same as those described in Chapter 2. 
4.3  Results 
Based on the specified inclusion and exclusion criteria (Figure 4.1 and Table 4.1), 1,851 
studies were identified initially and following further inspection of the abstract, 34 were 
retained for evaluation. Twenty-five of these studies were analysed, however, 8 studies 
could not be evaluated as they were published in Japanese or Turkish. 
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Figure 4. 1: Flow chart for the systematic review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EMBASE = 475 
 
MEDLINE = 145 
 
PUBMED = 1343 
Total publications after limiting to human subjects = 1981 
1851 articles 
 
Duplication = 130 
 
34 articles 
1265 Abstracts not meeting 
inclusion criteria 
552 Review articles, survey and 
letter 
 
10 articles excluded: 
8 articles published in 
Japanese (5) & Turkish (3)  
1 Authors were not looking 
at safety outcomes  
1 With data for not 
separately described 
 
1817 articles excluded after 
screening abstracts 
25 STUDIES INCLUDED 
COCHRANE = 18 
1 article added by 
manual search 
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Table 4. 1:Reasons for exclusion from the systematic review 
Reason Total 
Irrelevant article 1265 
Review, conference, survey 552 
Studies in Turkish and Japanese  8 
Studies not looking at safety outcomes  1 
Studies reporting the safety but the data for children not described 
separately 
1 
Total 1827 
 
4.3.1 Quality assessment 
The 25 studies that remained after screening were assessed; 15 RCTs with the Cochrane 
risk of bias tool [58] and 9 observational studies (4 prospective and 5 retrospective 
studies) with STROBE tool [60]. Eight RCTs were rated low-risk for all criteria [65-72]. 
The method of randomisation was inadequately described in 3 studies [73, 74, 76]. In 3 
RCTs, the risk of bias in the allocation concealment was high [73, 76, 78]. One RCT 
was rated high-risk in blinding of participants and personnel [78] (Figure 4.2). None of 
these RCTs were excluded from the systematic review. None of the observational 
studies (prospective and retrospective studies) were excluded. All studies were of 
sufficiently good quality for inclusion. There were no quality tools to assess the case 
report/series and determine the quality of these types of studies. 
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Figure 4. 2: Risk of bias summary 
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4.3.2 The study descriptions 
Twenty-five studies were included; 15 were randomised controlled trials [65-74, 76, 78-
81], 9 were cohort studies [51, 82, 84, 95-100] and one case series[101]. These studies 
involved more than 2,000 children aged from birth to 18 years. Most of the children 
were treated with lorazepam (1263, 42%) (Table 4.2). 
 
Table 4. 2: Antiepileptic drugs used in 25 studies 
Anti-epileptic drug used 
No. of studies 
(N =25)
* 
No. of children 
(N = 2983)
* 
Lorazepam 7 1263 
Diazepam 10 551 
Midazolam 9 418 
Levetiracetam 4 243 
Paraldehyde 2 93 
Diazepam + phenytoin 1 88 
Sodium valproate 3 60 
Phenobarbital 1 30 
* Some children and studies accounted more than once 
Of the 25 studies that monitored AEs, 19 reported more than one AE. The other 6 studies 
reported none (Table 4.3 and 4.4). A total of 203 AEs were reported, mainly associated with 
lorazepam (65 AEs) and diazepam (53 AEs). The most common AE reported was respiratory 
depression (101 children), mainly reported with diazepam (46 children) and lorazepam (38 
children) (Table 4.5). 
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Table 4. 3: Summary of 19 studies that reported AEs 
Reference Study design (no. of study) Age (Y) No. of children 
 
No. of AEs 
 
Midazolam vs diazepam Open label RCT (2) 
Single blind RCT (2) 
0.2-14 MDZ (Buccal):         280 
MDZ (IM):                 16 
DZP (PR):                270 
DZP (IV):                   16   
Total:                       592     
MDZ (Buccal):           8 
MDZ (IM):                 1 
DZP (PR):                  9 
DZP (IV):                  7   
Total:                      25    
Lorazepam vs diazepam Open label RCT (1) 
Double blind RCT (1) 
Prospective non randomised (1) 
0.1<18 LZP (IV):                 191 
LZP (PR):                    6 
DZP (IV):                174 
DZP (PR):                 19 
Total:                      390                  
LZP (IV):                30 
LZP (PR):                  0 
DZP (IV):                33 
DZP (PR):                  1 
Total:                      64                  
Lorazepam vs diazepam + 
PHT 
Open label RCT (1) 
 
1-12 LZP (IV):                  90 
DZP+PHT (IV):       88 
Total:                    178 
LZP (IV):                   4 
DZP+PHT (IV):         5 
Total:                         9 
Lorazepam vs paraldehyde Open label RCT (1) 
 
0.2-12 LZP (IN):                 80 
Paraldehyde (IM):   80 
Total:                      160 
LZP (IN):                 29 
Paraldehyde (IM):   21 
Total:                       50 
Lorazepam vs Lorazepam Open label RCT (1) 
 
6-14 IV:                            70 
IN:                            71 
Total:                     141 
IV:                              2 
IN:                              0 
Total:                         2 
Valproate vs phenobarbital Double blind RCT (1) 3-18 VAP (IV):                 30 
PB (IV):                    30 
Total:                        60 
VAP (IV):                  7 
PB (IV):                   22 
Total:                      29 
Diazepam vs diazepam Retrospective non randomised (1) 0.1-15 PR:                            48 
IV:                             33 
Total:                        81 
PR & IV:                   3 
Levetiracetam  Prospective (2) 
Retrospective  (2) 
38 
weeks-18 
Y 
243 (IV) 8 
Valproate  Retrospective  (2) < 9.6 30 (IV) 10 
Paraldehyde Case series 0.2-17 IV:                                9 
PR:                               3 
Both routes:                  1 
Total:                        13   
IV:                                3 
PR:                               0 
Both routes:                 0 
Total:                          3   
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Table 4. 4: Summary of six studies that reported no AEs 
Reference Study design (no. of study) Age (Y) No. of children 
 
Midazolam vs diazepam Open label RCT (3) 
Single blind RCT (1) 
0-15 MDZ (Buccal):         109 
MDZ (IN):                  56 
DZP (PR):                   49 
DZP (IV):                  118   
Total:                        332     
Lorazepam vs Lorazepam Open label RCT (1) 
 
0.2-14 IV:                             264 
Buccal:                      252 
IN:                             245 
Total:                        761 
Midazolam Prospective (1) 
 
0.9-12 IN:                                20 
 
Table 4. 5: Reported AEs from 19 studies 
Body system ADRs LZP DZP MDZ Others Total  
Respiratory Respiratory 
depression 
38* 46 7 DZP+PHT (5) 
Paraldehyde (4)*  
PB (1)  
101 
Cardiovascular Hypotension 27 - 1 Paraldehyde (20) 
VAP (2) 
50 
CNS  Lethargy - - - PB (17) 
VAP (3) 
  20 
Behavioural 
changes 
- - - LEV (7) 7 
Hyperactivity - 2 - - 2 
Somnolence - - - VAP (2) 2 
Others Nausea & vomiting - 3 - VAP (5) 
PB (4) 
12 
Salivation - 2 - - 2 
↑ Ammonia - - - VAP (2) 2 
Abnormal LFTs - - - VAP (1) 1 
Purities - - 1 - 1 
Thrombocytopenia - - - VAP (1) 1 
Leukopenia - - - VAP (1) 1 
Pain at injection site - - - LEV (1) 1 
Total     65 53 9 76 203 
*  Include three cases of hypoxia; two with lorazepam (LZP) and one with paraldehyde 
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4.3.2.1 Evidence from RCTs 
Fifteen randomised controlled trials published between 1995 and 2015 were analysed, 
including 10 open-label studies [66, 69, 71-74, 76, 78, 79, 81], 3 single-blind studies [65, 
68, 80], and 2 double-blind studies [67, 70]. All of these were 2-armed clinical trials 
except 2 studies – one of these had 3 arms [71] and the other had 4 arms [76]. Eight 
studies compared midazolam and diazepam. All randomised control trials included were 
conducted solely in the paediatric population (Table 4.6). 
Table 4. 6: Randomised controlled studies characteristics 
Study characteristics No. of studies 
(N = 15) 
No. of children 
(N = 2548)
 
Type of blinding   
Open label 10 1733 
Single blinded 3 482 
Double blinded 2  333 
Antiepileptic drugs compared   
Midazolam vs. diazepam 8 914 
Lorazepam vs. diazepam 2 334 
Lorazepam vs. paraldehyde 1 160 
Lorazepam vs. diazepam + phenytoin 1 178 
 Intravenous lorazepam  vs. intranasal lorazepam  1 141 
Intravenous lorazepam  vs. intranasal & buccal LZP 1 761 
Sodium valproate vs. phenobarbital 1  60 
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A. Midazolam versus diazepam 
Eight studies compared the safety between midazolam and diazepam; they involved 
over 800 children (466 on midazolam) aged between birth and 14 years old; five were 
open-label [66, 73, 74, 78, 79] and three single-blinded [65, 68, 80]. Four studies 
documented one or more AE(s) [65, 68, 73, 78], and four studies did not report any AEs 
in either group [66, 74, 79, 80] (Table 4.7).  
 
Table 4. 7: Summary of four studies that did not report AEs 
Reference, 
country  
Study design  Age (Y) No. of 
children  
AEDs Dose (mg/kg) 
Ashrafi et al., 2010, 
Iran [79] 
Open label RCT 0-12 49 
 
49 
MDZ  
 
DZP  
0.3-0.5 BUC 
 
0.5 PR 
Talukdar et al, 
2009, India, [80] 
Single blind RCT < 12 60 
 
 
60 
 
MDZ 
 
 
DZP 
0.2 BUC 
 
 
0.3 IV 
Mahmoudian and 
Zadeh,  
Mohammadi, 2004, 
Iran [74] 
Open label RCT 0.2-15  35 
 
 
35 
MDZ 
 
 
DZP 
0.2 (IN) 
 
 
0.2 (IV) 
Lahat et al., 2000, 
Israel [66]  
Open label RCT 0.6-12  21  
(26 episodes) 
 
23  
(26 episodes) 
MDZ 
 
 
DZP 
0.2 (IN) 
 
 
0.3 (IV) 
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A.1. Buccal midazolam versus rectal diazepam 
Three studies compared the safety of buccal midazolam to rectal diazepam in more than 
500 children aged between birth and 15 years. Two were open-label [73, 78] and one 
was single-blind[65]. 
The randomisation sequences, allocation concealment and definitions used in these 
three studies for convulsive status epilepticus and effective treatment were described in 
the previous chapter (the effectiveness of AEDs for CSE).  
McIntyre et al. (2005) conducted a three-year, multicentre randomised controlled, open-
label study in 177 children who attended an emergency department with active 
convulsions in the UK [78]. The safety outcome was the incidence of respiratory 
depressions within 1 hour of the initial dose of the study medications. The oxygen 
saturation and respiratory rate were documented at 5, 15 and 40 minutes of the initial 
dose of the study medications. The authors defined respiratory depression as a decrease 
of oxygen level or respiratory rate which leads to oxygen supply either by using face-
mask inflation or intubation after the initial dose of the study medications.   
Baysun et al. (2005) performed a prospective, single-centre study in Turkey involving 
43 children aged between 2 months and 12 years with acute tonic clonic seizures [73].  
They did not specify the safety outcomes in the methods. However, respiratory rate, 
heart rate and blood pressure were recorded at 5 and 10 minutes after the administration 
of the study medications. The definition of respiratory depression was not specified by 
the authors. 
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Mpimbaza et al. (2008) assessed buccal midazolam against rectal diazepam in 330 
children, aged between 3 months and 12 years, who attended an emergency department 
with prolonged seizures [65]. This was an eight-month, single-blind, single-centre study 
in Uganda. The safety outcome was the incidence of respiratory depression after the 
administration of the AEDs. The peripheral oxygen saturation was recorded at 0, 5, 10, 
20, 40 and 60 minutes after the administration of the study medications. Respiratory 
definition was defined as a fall in oxygen saturation to < 92% or a decrease in 
respiratory efforts which needs breathing to be supported. 
Eight of the 280 children who received buccal midazolam experienced AEs; 7 cases of 
respiratory depression and one case of pruritus. Nine of the 270 children who received 
rectal diazepam experienced respiratory depression. The total incidence of AEs was 
similar between the two groups (3% midazolam and 3.3% diazepam). The difference 
was not significant (RR: 0.84; 95% CI: 0.33 to 2.12; p = 0.7) (Table 4.8). 
The incidence of respiratory depression was lower with buccal midazolam in two 
studies [73, 78] and higher in the other study [65]. None of the differences were 
significant (Table 4.8). The pooled risk ratio showed no significance between the two 
groups (RR: 0.73; 95% CI: 0.28 to 1.91; p= 0.52).  
One study reported pruritus as an AE with midazolam [65] (Table 4.8). 
Admission to intensive care unit was documented in one study [78]. Two of the 92 
children (2%) who received buccal midazolam were admitted to ICU due to respiratory 
depression compared to three of the 85 children (3.5%) who received rectal diazepam 
(RR: 0.62; 95% CI: 0.11 to 3.6; p= 0.59). 
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The mortality rate was documented in one study [65].  Eight of the 165 children (5%) 
who received buccal midazolam died compared to 12 of the 165 children (7%) who 
were treated with rectal diazepam (RR: 0.67; 95% CI: 0.28 to 1.59; p= 0.35). However, 
all the deaths were documented to be due to status epilepticus itself (Table 4.8). 
In summary, the three studies showed no difference in the toxicity between buccal 
midazolam and rectal diazepam. The incidence of respiratory depression was 3-3.3%. 
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Table 4. 8: Buccal midazolam versus rectal diazepam  
Reference, 
country  
Study 
design  
Age (Y) No. of 
children  
AEDs Dose (mg/kg) All AEs 
(No. of children, %) 
RR (95% CI)  
P-value 
 
MDZ*                 DZP* 
Resp. depression 
(No. of children, %) 
RR (95% CI)  
P-value 
 
MDZ                       DZP 
Other AEs 
(No. of children, %) 
RR (95% CI) 
P-value 
 
MDZ                   DZP 
ICU admission 
(No. of children) 
RR (95% CI) 
P-value 
 
MDZ            DZP 
Deaths 
(No. of children) 
RR (95% CI) 
P-value 
 
MDZ            DZP 
McIntyre et 
al, 2005, UK 
[78] 
Open label 
RCT 
0.7-15 92  
 
85  
MDZ  
 
DZP 
0.5 BUC 
 
0.5 PR 
4 (4%)               6 (7%) 
 
0.62 (0.18-2) 
p = 0.44 
4 (4%)                  6 (7%) 
 
0.62 (0.18-2) 
p = 0.44 
 0                               0 (2)                    (3) 
 
0.62 (0.11-3.6) 
p = 0.59 
Data not available 
Baysun et al, 
2005, Turkey 
[73] 
Open label 
RCT 
0.2-12  23  
 
20 
MDZ  
 
DZP 
0.25 BUC 
 
0.3-0.5 PR 
1 (4%)               1 (5%) 
 
0.87 (0.06-13) 
p = 0.92 
1 (4%)                  1 (5%) 
 
0.87 (0.06-13) 
p = 0.92 
0                                0 Data not available Data not available 
Mpimbaza et 
al 2008, 
Uganda [65] 
Single 
blind RCT 
0.3- 12  
 
165  
 
165  
MDZ  
 
DZP 
0.5 BUC 
 
0.5 PR 
3 (2%)               2 (1%) 
 
1.5 (0.25-8.9) 
p = 0.65 
2 (1%)                  2 (1%) 
 
1 (0.14-7) 
p = 1 
1 (0.6%)88**                0 
 
3 (0.12-73.1) 
p = 0.5 
Data not available (8)                  (12) 
 0.67 (0.28-1.6) 
p = 0.35 
Total 3 0.3-15 280 
270 
MDZ  
DZP 
0.25- 0.5 BUC 
0.3-0.5 PR 
8 (3 %)         9 (3.3%) 
0.84 (0.33-2.12) 
p = 0.7 
7 (3%)               9 (3.3%) 
0.73(0.28-1.91) 
p = 0.52 
1 (0.6%)**                   0 
3 (0.12-73.1) 
p = 0.5 
(2)                    (3) 
0.62 (0.11-3.6) 
p = 0.59 
(8)                  (12) 
 0.67 (0.28-1.6) 
p = 0.35 
* MDZ: Midazolam, DZP: Diazepam   
** Pruritus                     
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Figure 4. 3: The safety of buccal midazolam versus rectal diazepam  
1. All AEs 
 
2. Respiratory depression 
 
3. Pruritus 
 
4. ICU 
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Figure 3.4: The safety of buccal midazolam versus rectal diazepam  (continue..) 
5. Deaths 
 
 
A.2. Intramuscular midazolam versus intravenous diazepam 
Portela et al. (2014) conducted a single-centre randomised controlled, single-blind study 
in Brazil involving 32 children aged between 2 months and 14 years[68]. The 
randomisation sequences, allocation concealment, convulsive status epilepticus 
definition and treatment successful definition for this study were described in the 
previous chapter (the effectiveness of AEDs for CSE).  
The authors did not specify the safety outcome however; any AEs were assessed in the 
first 10 minutes after drug administration. The following parameters were monitored 
from admission and every 5 minutes thereafter until seizure cessation and discharge; 
heart rate and oxygen level by pulse oximetry. The definition of respiratory depression 
was not given. 
One of the 16 children who received intramuscular midazolam experienced 
hypotension. Seven of the 16 children who received intravenous diazepam experienced 
AEs; 2 cases each of hyperactivity, vomiting and salivation and one case of nausea. The 
incidence of any AE was lower following intramuscular midazolam (6%) than 
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intravenous diazepam (44%); borderline statistically significant (RR: 0.14; 95% CI: 
0.02 to 1.03; p = 0.05) (Table 4.9).   
No children in either group required ICU admission and there were no reported cases of 
death. 
In summary, there was a borderline statistical difference in the risk of all AEs, 
favouring intramuscular midazolam. 
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Table 4. 9: Intramuscular midazolam versus intravenous diazepam 
Reference, 
country  
Study 
design  
Age 
(Y) 
No. of 
children  
AEDs Dose (mg/kg) All AEs 
(No. of children, 
%) 
RR (95% CI)  
P-value 
 
 
 
MDZ            DZP 
Hyperactivity 
(No. of children, 
%) 
RR (95% CI)  
P-value 
 
 
MDZ              DZP 
Vomiting 
(No. of children, 
%) 
RR (95% CI) 
P-value 
 
 
MDZ            DZP 
Hypotension 
(No. of 
children, %) 
RR (95% CI) 
P-value 
 
 
MDZ         DZP 
Salivation 
(No. of children, 
%) 
RR (95% CI) 
P-value 
 
 
MDZ            DZP 
Nausea 
(No. of children, 
%) 
RR (95% CI) 
P-value 
 
 
MDZ            DZP 
Portela et al, 
2014, Brazil 
[68] 
Single 
blind 
RCT 
0.2-14 16 
 
16  
MDZ  
 
DZP 
0.5 IM (max. 15mg) 
 
0.5 at 5mg/min IV  
(max. 10mg)  
1 (6%)      7 (44%) 
 
0.14 (0.02-1.03) 
p = 0.05 
0               2 (13%)* 
 
0.29 (0.01-3.86) 
p = 0.29 
0               2 (13%) 
 
0.29 (0.01-3.86) 
p = 0.29 
 1 (6%)          0 
 
3  (0.13-86.57) 
p = 0.49 
0             2 (13%)* 
 
0.29 (0.01-3.86) 
p = 0.29 
0%            1 (6%) 
 
0.33  (0.01-7.62) 
p = 0.49 
Total 1 0.2-14 16 
 
16 
MDZ  
 
DZP 
0.5 IM (max. 15mg) 
 
0.5 at 5mg/min IV  
(max. 10mg) 
1 (6%)      7 (44%) 
 
0.14 (0.02-1.03) 
p = 0.05 
0               2 (13%)* 
 
0.29 (0.01-3.86) 
p = 0.29 
0               2 (13%) 
 
0.29 (0.01-3.86) 
p = 0.29 
 1 (6%)           0 
 
3  (0.13-86.57) 
p = 0.49 
0             2 (13%)* 
 
0.29 (0.01-3.86) 
p = 0.29 
0                 1 (6%) 
 
0.33  (0.01-7.62) 
p = 0.49 
MDZ: midazolam, DZP: diazepam 
* Same children 
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B. Lorazepam versus diazepam  
Two studies that compared the safety between lorazepam and diazepam involved over 
300 children; one was open label [76], and one was double-blind [70].  
Respiratory depression was the only AE reported in both studies. It was most common 
in children who received intravenous diazepam (33 children). 
B.1. Lorazepam (IV) versus diazepam (IV) 
Two studies compared the safety of intravenous lorazepam to intravenous diazepam, 
they recruited a total of 334 children aged between one month and <18 years. 
The randomisation sequences, allocation concealment, convulsive status epilepticus 
definition and treatment successful definition for these studies were described in the 
previous chapter (4); section (2, I).  
Appleton et al. (1995) conducted a 12-month, single-centre, randomised, open-label 
study of 61 children aged between one month and 16 years who attended the emergency 
department with an acute tonic-clonic convulsion[76]. 
The safety outcome was the incidence of respiratory depression. The authors defined 
respiratory depression as requiring oxygen by using face-mask inflation or a decrease of 
respiratory effort and rate following seizure termination. 
In the second study, Chamberlain and colleagues assessed 273 children, aged from 3 
months through 17 years. One hundred and forty patients were given diazepam and 133 
lorazepam [70]. This was a 4-year, double-blind, randomised clinical trial conducted in 
the U.S. at 11 paediatric hospitals. The primary safety outcome was any respiratory 
4 The Safety of AEDs for convulsive status epilepticus (CSE) 
 
115 
 
depression within 10 minutes of the initial dose of the study medications. Respiratory 
depression was defined as a decrease in the respiratory effort and rate which led to 
oxygen supply. The secondary outcomes were incidences of aspiration pneumonia, time 
to recover consciousness, and incidence of sedation and agitation.  
Twenty-seven of the 160 children who received intravenous lorazepam experienced 
respiratory depression. Thirty-three of the 174 children who received intravenous 
diazepam experienced respiratory depression. The total incidence of respiratory 
depression was slightly lower with intravenous lorazepam (17%) than intravenous 
diazepam (19%), however, the difference was not statistically significant (RR: 0.57; 
95% CI: 0.11 to 3.07; p = 0.52) (Table 4.10). 
The data of other AEs and mortality rate were not reported.  
ICU admission was reported in one study[76]. Only children on intravenous diazepam 
were admitted to ICU due to the respiratory depression (8/34 children; RR: 0.07; 95% 
CI; 0 to 1.22; p = 0.07) (Table 4.10). 
In summary, these two studies showed no difference in the incidence of respiratory 
depression. However, no children on intravenous lorazepam were admitted to ICU due 
respiratory depression. The incidence of respiratory depression was 17-19%.  
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Table 4. 10: Intravenous lorazepam vs intravenous diazepam  
Reference, 
country  
Study 
design  
Age (Y) No. of 
children  
AEDs Dose (mg/kg) Respiratory 
depression 
(No. of children, %) 
RR (95% CI)  
P-value 
 
 
 
LZP                       DZP 
ICU admission 
(No. of children) 
RR (95% CI) 
P-value 
 
 
 
LZP                
DZP 
Appleton et 
al, 1995, UK 
[76] 
Open 
label 
Quasi-
RCTs 
0.1-16  27 
 
34 
Lorazepam 
 
Diazepam 
0.05-0.1  (IV)  
 
0.3-0.4 (IV)  
1 (4%)                7 
(21%) 
 
0.18 (0.02 – 1.39) 
p = 0.1 
 0                         8 
 
0.07  (0 – 1.22) 
p = 0.07 
Chamberlain 
et al., 2014, 
USA [70] 
Double 
blind 
RCT 
0.3-<18 133 
140 
Lorazepam  
Diazepam 
0.1 (IV), 
4 mg max. 
 
0.2 (IV),  
8 mg max. 
26 (20%)          26 
(19%) 
 
1.05 (0.65 – 1.72) 
p = 0.84 
Data was not 
available 
Total  0.1<18 160 
 
174 
LZP 
 
DZP 
0.05-0.1 (IV) 
Max 4 mg 
 
 
0.2-0.4 (IV) 
Max. 8 mg 
27 (17%)          33 
(19%) 
 
0.53 (0.14 – 2.03) 
p = 0.35 
0                           
8 
 
0.07  (0 – 1.22) 
p = 0.07 
 LZP: Lorazepam, DZP: Diazepam                         
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Figure 4. 4: The safety of lorazepam (IV) compared with diazepam (IV)  
1. Respiratory depression 
 
2. ICU admissions 
 
B.2. Lorazepam (PR) versus diazepam (PR) 
The study by Appleton et al. (1995) also compared rectal lorazepam and rectal 
diazepam in 25 children (a concurrent portion of this study, that examined intravenous 
lorazepam vs. intravenous diazepam, was described in the previous section) [18]. Six 
children received lorazepam and 19 received diazepam. 
Respiratory depression was only documented in one child treated with diazepam. A RR 
of 0.95 (95% CI: 0.04 to 20.78, p = 0.98), and he was admitted to ICU (RR: 0.57; 95% 
CI: 0.03 to 10.51, p = 0.71) (Table 4.11) 
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The data of other AEs and mortality rate were not reported.  This study showed no 
statistical difference in the incidence of respiratory depression between lorazepam and 
diazepam. 
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Table 4. 11: Lorazepam (PR) versus diazepam (PR) in one study 
Reference, 
country  
Study 
design  
Age (Y) No. of 
children  
AEDs Dose 
(mg/kg) 
Respiratory 
depression 
(No. of children, 
%) 
 
RR (95% CI)  
P-value 
 
 
LZP                DZP 
ICU admissions 
(No. of children) 
 
 
RR (95% CI)  
P-value 
 
 
 
LZP                   DZP 
Appleton et 
al., 1995, 
UK [76] 
Open 
label 
Quasi-
RCT 
0.1-16  6 
 
19 
LZP 
 
DZP 
0.05-0.1 (PR)  
 
0.3-0.4 (PR)  
 0                  1 (5%) 
0.95 (0.04 – 20.78) 
p = 0.98 
 (0)                        (1) 
0.57 (0.03 - 10.51) 
p = 0.71 
LZP: Lorazepam, DZP: Diazepam                        
C. Lorazepam versus paraldehyde 
Shafique and colleagues conducted a 12-month, single-centre, randomised, open-label 
study in sub-Saharan Africa to compare intranasal lorazepam and intramuscular 
paraldehyde [14]. One hundred and sixty children aged 2 months to 12 years who 
attended the paediatric emergency department with generalized convulsions continuing 
for at least 5 minutes were included. 
 The randomisation sequences, allocation concealment, convulsive status epilepticus 
definition and treatment successful definition were described in the previous chapter. 
The safety outcomes were the incidence of hypotension or hypoxia. Hypotension was 
defined as a reduction of 5 mm Hg or more for systolic and diastolic pressure. Hypoxia 
was defined as oxygen saturation (SpO2) level of <92% within 30 minutes of drug 
administration. 
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 Twenty-eight of the 80 children who received intranasal lorazepam experienced 29 
AEs; 27 cases suffered from hypotension and two from hypoxia (i.e. one child had 2 
AEs). 
Twenty-one of the 80 children who received intramuscular paraldehyde experienced 
AEs; 20 hypotension and one hypoxia. The total incidence of any AE following 
treatment with intranasal lorazepam was higher (35%) than with intramuscular 
paraldehyde (26%), but not statistically different (RR: 1.33; 95% CI: 0.83 to 2.14; p = 
0.23) (Table 4.12). 
The total incidence of hypotension was higher in the lorazepam group (34%) than the 
paraldehyde group (25%). Meta-analysis did not reveal any significant difference 
between the two groups (RR: 1.35, 95% CI: 0.83 to 2.2; p = 0.23) (Table 4.12). 
The risk of hypoxia was 2 times greater with lorazepam than paraldehyde. However, our 
meta-analysis showed no significant difference between the two groups (95% CI: 0.19 
to 21.62; p= 0.57) (Table 4.12). 
The data of other AEs, mortality rate and ICU admissions due to AEs were not reported. 
In summary, children receiving intranasal lorazepam as opposed to intramuscular 
paraldehyde were seen more often to have hypotension and hypoxia, however, this 
difference was not statistically significant. 
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Table 4. 12: Lorazepam (intranasal) vs paraldehyde (intramuscular) in one study 
Reference, country  Study 
design  
Age (Y) No. of 
children  
AEDs Dose  All AEs 
(No. of children, %) 
 
RR (95% CI)  
P-value 
 
 
 
LZP              Paraldehyde 
Hypotension 
(No. of children, %) 
 
RR (95% CI)  
P-value 
 
 
 
LZP              Paraldehyde   
Hypoxia 
(No. of children, %) 
 
RR (95% CI)  
P-value 
 
 
 
LZP              Paraldehyde  
Shafique et al., 2006, 
sub-Saharan Africa 
[72] 
Open label 
RCT 
0.2-12  80 
 
80 
LZP 
 
Paraldehyde 
100 μg/kg  (IN)  
 
0.2 ml/kg (IM)  
28 (35%)              21 (26%) 
1.33 (0.83 – 2.14) 
P = 0.23 
 27 (34%)            20 (25%) 
1.35 (0.83 – 2.2) 
P = 0.23 
 2 (3%)                     1 (1%) 
2  (0.19 – 21.62) 
p = 0.57 
LZP: Lorazepam 
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D. Intravenous lorazepam versus intravenous diazepam plus phenytoin (IV) 
A 2010 study compared the intravenous use of lorazepam with an intravenous 
combination of diazepam and phenytoin in a tertiary hospital in India [1]. The study was 
randomised and open-label. Phenytoin was given, 15 to 30 minutes after diazepam 
administration, even if seizures had not recurred. The study recruited 178 children aged 
between 1 and 12 years with convulsive status epilepticus lasting for at least 5 minutes. 
If IV access could not be obtained, the same dose of lorazepam and diazepam was given 
rectally. 
The safety outcome was incidence of respiratory depression. Respiratory depression 
was defined as a decrease in the respiratory effort and rate following the seizure 
termination, which needs oxygen supply or oxygen saturation less than 92%.  
Four of the 90 children who received intravenous lorazepam experienced respiratory 
depression compared to 5 of the 88 children who received the intravenous combination 
of diazepam and phenytoin. The total incidence of respiratory depression was slightly 
lower with intravenous lorazepam (4%) than intravenous diazepam (6%), but not 
statistically significant (RR: 0.78; 95% CI: 0.22 to 2.82; p = 0.71) (Table 4.13). There 
were no cases required ICU admissions for mechanical ventilation due to respiratory 
depression. 
The data of other AEs and mortality rate were not reported.  
In summary, intravenous lorazepam was seen less often to be associated with respiratory 
depression compared to the intravenous combination of diazepam and phenytoin; 
however, this difference was not statically significant.  
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Table 4. 13: Intravenous lorazepam versus intravenous diazepam plus phenytoin 
Reference, 
country  
Study 
design  
Age 
(Y) 
No. of 
children  
AEDs Dose (mg/kg) Respiratory depression 
(No. of children, %) 
 
RR (95% CI)  
P-value 
 
LZP                         DZP+PHT 
Sreenath 
et al., 
2010, 
India [81] 
Open 
label 
RCT 
1–12  90 
 
88 
LZP 
 
DZP+PHT 
0.1 (IV)  
 
0.2 + 18/15–30 min  (IV)  
  
4 (4%)                           5 (6%) 
0.78 (0.22–2.82) 
P = 0.71 
LZP: Lorazepam, DZP: Diazepam, PHT: Phenytoin 
E.  Intravenous lorazepam versus intranasal lorazepam 
Two open-label studies compared the safety of intravenous and intranasal lorazepam; 
they involved over 600 children (334 on intravenous lorazepam) aged between 2 
months and 14 years. Of these, one study reported two AEs for intravenous 
lorazepam[69] while the other study did not report AEs in either group (Table 4.14) [71].  
 
Table 4. 14: Summary of study that did not report AEs 
Reference, 
country  
Study design  Age (Y) No. of 
children  
AEDs Dose (mg/kg) 
Lissauer et al. ,2015, 
Malawi [71] 
Open label 0.2-14 264 
245 
LZP 
LZP 
0.1 (IV) 
0.1 (IN) 
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Arya et al. (2011) conducted the 7-month, randomised, open-label, single-centre study 
in India [11]. The researchers recruited 141 children aged between 6 and 14 years who 
attended the emergency department with an acute tonic-clonic convulsion and compared 
the administration of intravenous versus intranasal lorazepam. The safety outcomes were 
hypotension within 1 hour of the drug’s administration and incidence of respiratory 
depression needing ventilation.  
Two of the 70 children (3%) who received intravenous lorazepam experienced 
respiratory depression. There were no other AEs reported in either group (Table 4.15). 
The intranasal route appeared to be safer than the intravenous route in terms of respiratory 
depression; however, the difference was not significant (p = 0.29).  
Table 4. 15: Intravenous lorazepam versus intranasal lorazepam  
Reference, 
country  
Study 
design  
Age 
(Y) 
No. of 
children 
AED Dose (mg/kg) Respiratory 
depression 
(No. of children, 
%) 
 
 
 
IV                         
IN 
RR (95% CI)  
P-value 
 
Arya et al., 
2011, India 
[69] 
Open 
label  
6-14  70 
 
 
 
71 
LZP 
 
 
 
LZP 
0.1 (IV), 4 mg 
max. 
 
 
0.1/30-60 sec (IN) 
 2 (3%)                    
0 
 
5.07 (0.25-103.76) 
p = 0.29 
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F. Intravenous lorazepam versus buccal lorazepam 
The Lissauer study described in the previous section (intravenous vs. intranasal 
lorazepam) also compared intravenous versus buccal lorazepam [13]. No children had 
respiratory depression nor required ventilation. The other AEs were not reported. 
Forty-seven (18%) of the 264 children received intravenous lorazepam and died 
compared to 39 (15.5%) of the 252 children treated with buccal lorazepam (RR: 1.15; 
95% CI: 0.78 to 1.7; p = 0.48) (Table 4.16). However, it was documented to be due to 
status epilepticus itself. 
Table 4. 16: Intravenous lorazepam versus buccal lorazepam  
Reference, 
country  
Study 
design  
Age 
(Y) 
No. of 
children 
AED Dose 
(mg/kg) 
Deaths 
(No. of children, %) 
 
IV                         BUC 
RR (95% CI)  
P-value 
 
Lissauer et 
al. ,2015, 
Malawi 
[71] 
Open 
label 
0.2-14 264 
 
252 
LZP 
 
LZP 
0.1 (IV) 
 
0.1 (BUC) 
 
 47 (18%)       39 
(15.5%)  
 
 
1.15 (0.78-1.7) 
p = 0.48 
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G. Valproate versus phenobarbital 
An Iranian study compared intravenous valproate to intravenous phenobarbital in the 
treatment of acute prolonged seizures at 2 centres in 2012 [67]. This randomised, 
double-blind study took place over 2 years.  It involved 60 children aged between 3 and 
16 years who attended the emergency room with seizures lasting more than 5 minutes, 
that had not been controlled by intravenous diazepam (0.2mg/kg). 
The following parameters were measured from the starting of treatment to seizure 
termination: pulse, blood pressure, respiratory effort (before treatment, at the end of 
treatment and at 5, 10, 20, and 30 minutes after starting treatment), and electrocardiogram 
baselines. Children who experienced hypotension or cardiac dysrhythmias were 
excluded and treatment was stopped. The authors did not define the respiratory 
depression, hypotension, and cardiac dysrhythmia. 
Seven of the 30 children who received intravenous valproate experienced 7 AEs; 3 cases 
each of lethargy and vomiting and one case of hypotension. By contrast, 22 of the 30 
children who received phenobarbital experienced 22 AEs; 17 cases of lethargy, 4 cases 
of vomiting, and one case of respiratory depression (Table 4.17). 
The total incidence of AEs following treatment with intravenous valproate was 
significantly lower (23%) than those following treatment with intravenous phenobarbital 
(73%) (RR: 0.32; 95% CI: 0.16 to 0.63; p = 0.001).  
Lethargy was the most common AE reported in both groups, with a lower occurrence in 
the valproate group (3 children, 10%) compared to the phenobarbital group (17 children, 
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57%). This was a statistically significant difference (RR: 0.18, 95% CI: 0.06 to 0.54, p = 
0.002).  
Vomiting was the second most common AE, with a similar occurrence between both 
groups, 10% in the valproate group and 13% in the phenobarbital group (RR: 0.75, 95% 
CI: 0.18 to 3.07, p = 0.69). 
Respiratory depression was reported in one case of intravenous phenobarbital; however, 
it was not reported amongst the valproate group (RR: 0.33, 95% CI: 0.01 to 7.87, p = 
0.5). Hypotension was only documented in one child treated with intravenous valproate 
with a risk ratio of 3 (95% CI: 0.13 to 70.83; p = 0.5).  
The data for mortality and ICU admission due to AEs were not available (Table 4.17). 
In summary, no child receiving intravenous valproate experienced respiratory 
depression as opposed to a single child receiving intravenous phenobarbital, the 
difference was not significant. However it appeared overall, when looking at all AEs, 
that valproate is significantly safer (p = 0.001). 
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Table 4. 17: Valproate (IV) versus phenobarbital (IV) in one study 
Reference, 
country  
Study 
design  
Age (Y) No. of 
children 
AED Dose (mg/kg) All AEs 
(No. of children, %) 
 
 
RR (95% CI)  
P-value 
 
 
VAP                   PB 
Lethargy 
(No. of children, %) 
 
 
RR (95% CI)  
P-value 
 
 
VAP                            PB 
Vomiting 
(No. of children, %) 
 
 
RR (95% CI)  
P-value 
 
 
VAP                         PB 
Respiratory 
depression 
(No. of children, %) 
 
RR (95% CI)  
P-value 
 
 
VAP                        PB 
Hypotension 
(No. of children, 
%) 
 
RR (95% CI)  
P-value 
 
 
VAP                  PB 
Malamiri et 
al. ,2012, 
India [67] 
Double-
blind 
RCT 
3-16 30 
 
30 
VAP 
PB 
20 at 5 - 6mg/min (IV) 
20 at 60 - 100 mg/min (IV) 
 
7 (23%)           22 
(73%) 
0.32 (0.16 – 0.63) 
p = 0.001 
3 (10%)             17 (57%) 
0.18 (0.06 – 0.54) 
p = 0.002 
 3 (10%)           4 (13%) 
0.75 (0.18 – 3.07) 
p = 0.69 
0                         1 (3%) 
0.33 (0.01 – 7.87) 
p = 0.5 
1 (3%)                  0 
3 (0.13 – 70.83) 
p = 0.5 
VAP: Valproate, PB: Phenobarbital 
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4.3.2.2 Evidence from prospective observational studies 
Four prospective observational studies involved 156 children aged between 2 months 
and 18 years; one compared 2 AEDS (lorazepam and diazepam) [84]. All  included 
studies, except one [99], were conducted solely in the paediatric population. 
Levetiracetam was the most frequently studied drug (Table 4.18). Seven AEs were 
reported; 4 were associated with intravenous levetiracetam. Respiratory depression that 
resulted in PICU admission was reported in 3 children who were administered 
intravenous lorazepam.   
Table 4. 18: Prospective observational studies characteristics 
Study characteristics No. of studies 
(N = 4)
* 
No. of children 
(N = 156)
* 
Antiepileptic drugs used   
levetiracetam 2 88 
diazepam 1 17 
lorazepam 1 31 
midazolam 1 20 
    * Some children and studies accounted more than once.        
The first of the these four studies was a prospective, comparative, non-randomised 
study conducted in the UK by Wassmer and colleagues which compared intravenous 
lorazepam and intravenous diazepam [84]. This study involved 48 children aged 5 
months to 11 years with convulsive status epilepticus.  
Of these 48 children, 31 received intravenous lorazepam and 17 intravenous diazepam. 
AEs were reported in 3 children (10%) who experienced respiratory depression after 
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receiving intravenous lorazepam and were transferred to PICU. No other AEs were 
reported (Table 4.19). 
The second observational study, conducted in the UK by McTague and colleagues 
evaluated the safety of intravenous levetiracetam [51]. This study involved 45 children 
who were aged between 2 months and 18.8 years (mean 7.1 years) with acute repetitive 
seizure or status epilepticus. Two children had non-convulsive status epilepticus and 
were excluded from the analysis. Three of 43 children exhibited changed, aggressive 
behaviour. The treatment was discontinued in one of these three children. There were no 
other AEs reported (Table 4.19). 
The third study, conducted in the US by Wheless and colleagues evaluated the safety of 
intravenous levetiracetam [99]. This study involved 45 patients aged between 4 and 32 
years (mean 14 years). One child aged 16 years with mental retardation experienced 
pain at the site of intravenous administration. The levetiracetam was discontinued and 
the child was removed from the study. No AEs were reported in the other children 
(Table 4.19). 
The fourth study, conducted in the UK by Conroy and colleagues evaluated the safety of 
intranasal midazolam in 20 children aged 10 months to 12 years who attended the 
emergency department with seizures [100]. No AEs were reported in this study (Table 
4.19). 
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Table 4. 19: The safety outcome in the prospective observational studies 
Reference, country  Study 
design  
Age 
(Y) 
No. of 
children  
AEDs Dose (mg/kg) 
and route 
All 
AEs 
Respiratory 
depression 
Behavioural 
change 
Pain at the 
administration site 
ICU admissions 
due to AEs 
Wassmer et al, 
2002, UK, [84] 
Prospective 
comparative 
0.5- 11  
 
31 
 
17 
Lorazepam 
 
Diazepam 
0.1 IV 
 
0.3 IV 
3 
 
0 
3 
 
0 
0 
 
0 
0 
 
0 
3 
 
0 
McTague, A., et al, 
2012, UK[51] 
Prospective 0.2-
18.8 
(Mean 
7.1) 
43 Levetiracetam 14.4 (median) IV 3 0 3 0 0 
Wheless, J.W., et al, 
2009, USA[99] 
Prospective 4-32  
(Mean 
14) 
45 Levetiracetam 20-60 IV 1 0 0 1 0 
Conroy, S., et al, 
2000, UK[100] 
Prospective 0.9-12 20 Midazolam 0.2 IN 0 - - - 0 
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4.3.2.3 Evidence from retrospective observational studies  
Five retrospective studies involved 266 children aged from birth to 18 years; one 
compared 2 routes (IV and PR diazepam)  [82]. Levetiracetam was the most frequently 
studied drug (Table 4.20). Overall, seventeen AEs were reported; 10 were associated 
with intravenous valproate. Respiratory depression that resulted in PICU admission was 
reported in 3 children who were administered diazepam. 
Table 4. 20: Prospective observational study characteristics 
Study characteristics No. of studies 
(N =5)
* 
No. of children 
(N = 266)
* 
Antiepileptic drugs used   
levetiracetam 2 155 
diazepam 1 81 
sodium valproate 2 30 
    * Some children and studies accounted more than once.        
Garr and colleagues conducted a retrospective study to compare the effectiveness of 
rectal and intravenous diazepam, in children aged one month to 15 years with tonic-
clonic convulsions in the UK [82]. This study involved 81 children, of whom 48 
received rectal diazepam, while 33 received intravenous diazepam. The safety outcome 
was respiratory depression. Three of 81 children (4%) experienced respiratory 
depression and required admission to ICU; they all received two doses of diazepam in 
addition to rectal paraldehyde and intravenous phenytoin. Of these 3 children, one child 
received two doses of rectal diazepam and the authors did not state the route of 
administration for the other 2 children.  
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İşgüder and colleagues conducted a retrospective study to evaluate the effectiveness and 
safety of intravenous levetiracetam in Turkey [95]. This study involved 133 children 
aged one month to 18 years with acute repetitive seizures. Three of the 133 children 
(2%) experienced behavioural changes which resolved after dose reduction. No other 
AEs were reported.  
Fallah and colleagues conducted a retrospective study in Iran to evaluate the 
effectiveness and safety of intravenous sodium valproate [97].  This study involved 11 
children aged 3 to 9.6 years admitted to the emergency department with acute repetitive 
seizures. Two of the children (18%) experienced transient nausea and vomiting. There 
were no other AEs reported. 
An American study conducted by Khan and colleagues compared the effectiveness and 
safety of intravenous levetiracetam in 22 neonates aged 37.5 to 41.2 weeks [96]. One 
child (5%) experienced irritability and subsequently received pyridoxine at 50 mg once 
daily.  
The last study was conducted in Spain by Campistol and colleagues to evaluate the 
effectiveness and safety of intravenous sodium valproate [98]. This study involved 19 
children aged less than 7 years. Seven of the 19 children (37%) experienced 8 AEs; two 
cases of hyperammonaemia, two cases of somnolence; one case of hypotension, and one 
case with abnormal liver function tests, thrombocytopenia and leukopenia. Intravenous 
valproate treatment was stopped in one child due to the abnormal liver function tests. 
None of the children were transferred to the ICU due to the AEs. 
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Table 4. 21: The safety outcome in the retrospective studies 
Reference, 
country  
Study design  Age 
(Y) 
No. of 
children  
AEDs Dose 
(mg/kg) and 
route 
All 
AEs 
Hypotension Respiratory 
depression 
Behavioural 
change 
Abnormal  
liver 
function 
tests 
Others ICU 
admissions 
due to AEs 
Garr et al., 
1999, UK, 
[82] 
Retrospective 
comparative 
0.1-15  
 
48  
 
33 
Diazepam 
 
Diazepam 
0.4 PR 
 
0.4 IV 
 
3 
 
0 
 
3 
 
0 
 
0 
 
0 
 
3 
İşgüder, R., et 
al, 
2014,Turkey 
[95] 
Retrospective 0.1-18 133 Levetiracetam 10-20  
over 15 min 
IV 
3 0 0 3 0 0 0 
Fallah et al., 
2012, Iran 
[97] 
Retrospective 3-9.6 11 Valproate 15      at 
3mg/kg/min 
IV 
2 0 0 0 0 Nausea and 
vomiting (2) 
0 
Khan et al., 
2011, 
USA[96] 
Retrospective 38-41 
weeks 
22 Levetiracetam 50 (20 pts) 
20 (1 pt.) 
10 (1 pt.) 
IV 
1 0 0 1 0 0 0 
 
Campistol et 
al., 1999, 
Spain  [98] 
Retrospective 0-7 19 Valproate 20 at  
1mg/kg/hr  
IV 
8 1 0 0 1 ↑ Ammonia (2) 
Somnolence (2) 
Thrombocytopenia 
(1) 
 leukopenia (1) 
0 
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4.3.2.4 Case reports/series  
This systematic review identified one case series which was reported by Curless and 
colleagues [101]. It discussed the effectiveness and safety of paraldehyde in 13 children 
aged from 2 months to 17 years, 9 children received the medicine intravenously and 3 
rectally. One child received it by both routes .  
Three of the children, with ages ranging from 7 months to 13 years, developed 
respiratory depression during or within a few minutes after receiving a loading dose of 
0.3 ml/kg of intravenous paraldehyde. All these children were intubated and returned to 
normal breathing within one hour (Table 4.22).  
One other child, aged one year, died. This was reported to be due to the status 
epilepticus. 
Table 4. 22: Paraldehyde AEs in case series 
Reference, 
country  
Patient age 
(Y) 
Dose of IV paraldehyde 
(ml/kg) 
AE Treatment 
Curless et al. 
1983, US 
[101] 
13 2.5 Respiratory depression Intubated 
2.4 0.35 Respiratory depression Intubated 
0.7                     0.3 Respiratory depression Intubated 
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4.3.3 Respiratory depression 
Respiratory depression is a serious AE. In the RCTs and prospective observational 
studies this occurred in 95 children. Table 4.23 showed the three most common AEDs 
associated with respiratory depression. 
Table 4. 23: Respiratory depression in RCTs and prospective observational studies 
Routes Midazolam 
(No. of children experienced 
respiratory depression / No. 
of children receiving 
AEDs, %) 
Diazepam 
(No. of children experienced 
respiratory depression / No. 
of children receiving 
AEDs, %) 
Lorazepam  
(No. of children experienced 
respiratory depression / No. 
of children receiving 
AEDs, %) 
Buccal 7/280 (2.5%) - - 
PR - 10/289 (3.4%) - 
IV - 33/174 (19%) 38/502 (8%) 
Total  7/280 (2.5%) 43/463 (9%) 38/502 (8%) 
 
Buccal midazolam and rectal diazepam were associated with the lowest risk of 
respiratory depression (2.5%). Intravenous lorazepam was associated with a 
significantly lower risk of respiratory depression than intravenous diazepam (RR; 0.7; 
95% CI: 0.55 to 0.87; p < 0.0001). 
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4.4 Discussion 
The studies included in this review differed broadly in the reporting of AEs; some 
studies reported none whereas other studies reported at least one AE. In general, AEs 
were more frequently reported in the randomised control trials than in the cohort studies. 
Respiratory depression was the most commonly reported AE, mainly in association with 
benzodiazepines. Variation in the reporting of respiratory depression, due to 
benzodiazepines, was noted. Respiratory depression following diazepam (PR or IV), 
lorazepam (IN), and midazolam (buccal, IV, IN or IM) was not reported in 6 studies [66, 
68, 72, 74, 79, 80]. In contrast, it was reported following lorazepam (IV), midazolam 
(buccal), diazepam (PR, IV) in 5 studies [65, 73, 76, 78, 90]. This variation of the 
respiratory depression incidence may be due to the inclusion criteria of some of the 
studies. For example, studies that did not report respiratory depression excluded 
children who had received benzodiazepines as a prehospital treatment. Children who 
had received benzodiazepines, and whose seizures were not controlled before arriving at 
the hospital, are at a higher risk of respiratory depression. In children who suffered from 
acute tonic seizures, the respiratory depression may have been a complication either of 
their prolonged seizures or an AE of the benzodiazepine treatment [102]. 
Respiratory depression was most common with intravenous route however, its incidence 
was significantly lower with intravenous lorazepam (8%) compared to intravenous 
diazepam (19%) (p< 0.0001). 
This review showed no difference in the rate of respiratory depression between buccal 
midazolam and rectal diazepam. However, based on the results of the previous 
systematic review (Chapter 4), buccal midazolam was more effective in controlling 
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seizures in children suffering from acute tonic-clonic seizures than rectal diazepam 
(p<0.04). Therefore, when comparing the safety and effectiveness of both medications, 
our results show that buccal midazolam should be the first choice for treating acute 
tonic-clonic seizures in children, if  intravenous access is difficult to obtain [79]. 
Looking at the results reported in the previous chapter (Chapter 4), both intravenous 
medications were equally effective in treating acute tonic-clonic seizure. However, 
children given lorazepam were less likely to need additional dose(s) or AEDs to 
terminate their seizures, and were also less likely to have further seizures after drug 
administration. Therefore, intravenous lorazepam has better overall effectiveness and 
safety in treating acute tonic-clonic seizures compared to intravenous diazepam. 
Respiratory depression was not reported in children who received buccal or intranasal 
lorazepam. These routes however, compared to intravenous lorazepam, were less 
effective and more likely to require additional dose(s) or further AEDs to terminate the 
seizure when compared to intravenous lorazepam, as discussed in Chapter 4. The main 
aim of treating acute tonic clonic seizures is to terminate the seizure quickly, to prevent 
the seizure from developing into status epilepticus, and to avoid the risk of respiratory 
depression due to the prolonged seizures [86, 87, 102]. Therefore, the effectiveness and 
safety profile of intravenous lorazepam suggest that intravenous delivery may be the 
best route for this drug [83].   
Few studies that evaluated the safety of second line treatment (VAP, PB, LEV) were 
identified in this review. Our results identified one randomised control study that 
compared safety between intravenous valproate and intravenous phenobarbital; it 
showed that no child on intravenous valproate had respiratory depression. Moreover, 
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when looking at all AEs, it appeared that intravenous valproate was significantly safer 
than intravenous phenobarbital (p = 0.001). This could be because all children on 
intravenous valproate received a rapid loading dose (less than 20 minutes). Previous 
studies recommended that seizures be controlled in less than 30 minutes to reduce the 
risk of mortality and morbidity, suggesting that a rapid loading dose of intravenous 
valproate (less than 20 minutes) may the safest technique to stop seizures in children 
[103-105]. 
There were no cases of respiratory depression in children who received intravenous 
levetiracetam. However, no randomised control trials have been published that 
compared the safety of levetiracetam with other second-line agents for treating acute 
tonic-clonic seizures in children. 
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4.5 Limitations 
There were limitations in the studies that were identified in this systematic review. The 
majority were open label, which may affect the quality of a study and introduce bias. 
Not all studies included a definition of respiratory depression. Also, there was a 
variation in respiratory depression in the studies that defined this AE. Few randomised 
control trials were identified for the safety of second-line treatments; thus, the results of 
these studies should be interpreted with caution. 
4.6 Conclusions 
Respiratory depression was documented mainly with benzodiazepines. There were no 
differences in the incidences of respiratory depression between buccal midazolam and 
rectal diazepam. However, buccal midazolam is more effective than rectal diazepam, so 
is the preferred choice for acute tonic-clonic including CSE as 1
st
 line treatment. 
Intravenous lorazepam was less likely to be associated with respiratory depression when 
compared to intravenous diazepam. Intravenous lorazepam is the drug of choice where 
there is IV access.  More randomised control trials are needed to compare the safety of 
second-line treatments. 
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CHAPTER 5: CONCLUSION 
5.1 Introduction 
Status epilepticus (SE) is a serious neurological emergency associated with mortality 
and morbidity [106-109]. Effective management of acute tonic-clonic seizures including 
CSE should be given to all patients whose seizures have lasted ≥ 5 minutes and 
certainly those who attend the emergency department to prevent progression to status 
epilepticus [59]. Acute tonic-clonic seizures including CSE often requires IV, IM, PR, 
IN or buccal AEDs. An understanding of the comparative effectiveness and safety of 
the different AEDs and routes will guide clinicians when selecting an appropriate 
treatment for children.  
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5.2 Summary of findings 
In the first and the second systematic review, 25 studies were identified and were 
evaluated to assess the effectiveness and safety of AEDs for acute tonic-clonic seizures 
including CSE in children (Chapter 3&4).  
Buccal midazolam was more effective than rectal diazepam in terminating seizures with 
success rate ranging from 53% to 100%. Moreover, it was associated with a lower 
recurrence rate of seizures (ranging from 6% to 8%) and significantly less likely to 
require an additional AED (ranging from 22% to 36%).  
There were no differences in the incidence of respiratory depression between both 
groups; incidence was 3%-3.3%.  
Also, administering buccal midazolam is easier for parents, healthcare and other 
professionals and is more socially acceptable in comparison to the rectal method.  
Therefore, buccal midazolam is the preferred choice for acute tonic-clonic seizures 
including CSE as 1
st
 line treatment.  
When assessing the intravenous AEDs, intravenous lorazepam and intravenous 
diazepam were equally effective (RR: 1.02 & p = 0.73). Respiratory depression was 
most common with the intravenous route; however, lorazepam was less likely to be 
associated with respiratory depression compared to intravenous diazepam (8% vs 19%). 
Intravenous lorazepam was superior to sublingual/buccal (83% vs 46%) or intranasal 
lorazepam (82% vs 63%). It was more effective and less likely to require additional 
dose(s) or AEDs to terminate the seizures. This suggests that buccal lorazepam is poorly 
absorbed. As previously mentioned, a pharmacokinetic study conducted by Anderson 
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et.al has shown that lorazepam was slowly absorbed following buccal administration 
[85]. Peak absorption following buccal administration was at 180 minutes, suggesting 
that this may not be the best route for treating acute seizures [85]. These results suggest 
that intravenous administration is the best route for lorazepam when treating seizures in 
children.  
Few RCTs were identified that evaluated second-line treatment: intravenous valproate, 
phenobarbital and phenytoin.    
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5.3 Implications for practice 
I would suggest the following recommendations for out of hospital use and for 
healthcare professionals working in children’s hospitals:  
 Buccal midazolam is the preferred choice for acute tonic-clonic seizures including 
CSE as 1
st
 line treatment when intravenous access is difficult or is yet to be obtained.   
 Intravenous lorazepam is the treatment of choice for children with CSE who have 
IV access. 
 Training programmes are essential for paramedics and parents to deal with 
emergency treatment of status epilepticus. This will help medical professionals 
working in children’s hospitals to decrease the risk of morbidity and mortality of 
status epilepticus.  
 Based on this thesis, I am planning to establish a Saudi Arabia epilepticus working 
group. This group will involve pediatricians specialising in epilepsy and also 
emergency department physicians. It will work with authorised hospital committees 
to develop guidelines for status epilepticus treatment. 
 Develop national guidelines for treatment of status epilepticus in Saudi Arabia. 
5.4 Implications for future research 
 Researchers need to agree a universal definition of the stages of status epilepticus; 
early stages, established, refractory and super-refractory status epilepticus. 
 Researchers need to give a standard definition of treatment outcomes, especially the 
seizures recurrence rate; since 5 studies in this thesis did not define recurrence. 
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 Conduct surveys in Middle East countries about the AEDs used in status epilepticus 
in children. 
 Conduct more RCTs in Middle East countries to evaluate the effectiveness and 
safety of AEDs for acute tonic-clonic seizures including CSE in children; since 
limited numbers of studies have been conducted in this region.  
 More RCTs are needed to compare the effectiveness and safety of second-line 
treatment for acute tonic-clonic seizures including CSE in children. 
 A previous study in adults has shown similar efficacy between intravenous 
levetiracetam and intravenous lorazepam[110]. However, no such study has been 
conducted in children. Therefore, it is important to compare the efficacy of 
intravenous levetiracetam with intravenous lorazepam in children. 
 Intravenous lacosamide also is thought to have good effectiveness in the treatment 
of status epilepticus. There were up to 19 published articles on the use of 
intravenous lacosamide (10 case reports and 9 retrospective studies)[111]. 
Randomized controlled studies are needed to compare the effectiveness and safety 
of intravenous lacosmaide and other AEDs used for the management of acute tonic-
clonic seizures such as intravenous diazepam, lorazepam, phenytoin, phenobarbital, 
sodium valproate and levetiracetam in children.  
 More RCTs are required to evaluate the use of paraldehyde in children with 
convulsive status epilepticus. 
 More studies are required to clarify the role of parents and paramedics in treating 
convulsive status epilepticus out of hospital. 
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APPENDIX A: SYSTEMATIC REVIEW ONE: FOREST 
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A. Midazolam versus diazepam 
A.1. Buccal midazolam vs intravenous diazepam 
1. Successful seizure control 
 
2. Additional AEDs 
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A.2. Intramuscular midazolam versus intravenous diazepam 
1. Successful seizure control 
 
2. Additional dose(s) 
 
3. Additional AEDs 
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B. Lorazepam versus diazepam 
B.1. Rectal lorazepam versus rectal diazepam 
1. Successful seizure control 
 
2. Additional dose(s) 
 
3. Additional AEDs 
 
4. Seizure recurrence 
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B.2. Sublingual lorazepam versus rectal diazepam 
1. Successful seizure control 
 
2. Additional dose(s) 
 
3. Seizure recurrence 
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C. Intranasal lorazepam versus intramuscular paraldehyde 
1. Successful seizure control 
 
2. Additional AEDs 
 
3. Seizure recurrence 
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D. Intravenous lorazepam versus intravenous diazepam plus phenytoin 
1. Successful seizure control 
 
2. Additional dose(s) 
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E. Intravenous lorazepam versus buccal lorazepam 
1. Successful seizure control 
 
2. Additional dose(s) 
 
3. Additional AEDs 
 
4. Seizure recurrence 
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F. Intravenous valproate versus intravenous phenytoin 
1. Successful seizure control 
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G. Intravenous valproate versus intravenous phenobarbital 
1. Successful seizure control 
 
2. Seizure recurrence 
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APPENDIX B: SYSTEMATIC REVIEW TWO: FOREST 
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A. Midazolam versus diazepam 
A.1. Intramuscular midazolam versus intravenous diazepam 
1. All AEs 
 
2. Vomiting 
 
3. Hyperactivity 
 
4. Salivation 
 
5. Nausea 
 
6. Hypotension 
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B. Lorazepam versus diazepam 
1. Lorazepam (PR) versus diazepam (PR)  
 
2. ICU admission 
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C. Intranasal lorazepam versus intramuscular paraldehyde  
1. All AEs 
 
2. Hypotension 
 
3. Hypoxia 
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D. Intravenous lorazepam versus intravenous diazepam plus phenytoin 
(IV) 
1. Respiratory depression 
 
E. Intravenous lorazepam versus intranasal lorazepam 
1. Respiratory depression 
 
F. Intravenous lorazepam versus buccal lorazepam 
1. Deaths 
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G. Valproate versus phenobarbital 
1. All AEs 
 
2. Respiratory depression 
 
3. Hypotension 
 
4. Vomiting 
 
5. Lethargy 
 
 
